Breast cancer therapy in China: Introducing the Special Collection

This special issue indirectly reflects the medical level and research hotspots of breast cancer experts in China in recent years as well as the treatment level and disease outcome of patients with breast cancer in China, allowing readers to appreciate the achievements made in the field of breast cancer in China in recent years and to identify the gaps in the international field.

Type-I protein arginine methyltransferase inhibition primes anti-programmed cell death protein 1 immunotherapy in triple-negative breast cancer

BACKGROUND

Immune-checkpoint blockade (ICB) therapy shows promise for treating aggressive triple-negative breast cancer (TNBC). However, only some patients benefit from ICB, revealing an urgent need for identifying novel strategies for sensitizing patients to ICB. Previously, the authors demonstrated that type-I protein arginine methyltransferases (PRMTs) regulated antiviral innate-immune responses in TNBC by altering RNA splicing. This study aimed to explore the effects of targeting type-I PRMTs on the tumor microenvironment (TME) and the efficacy of ICB therapy against TNBC.

METHODS

Single-cell transcriptomic analysis was performed to investigate the effects of type-I PRMT inhibition on the TME, especially T-cell subsets. Single-cell T-cell receptor sequencing was performed to analyze the diversity and dynamics of the T-cell repertoire. A syngeneic murine model of TNBC was used to evaluate the therapeutic efficacy and immune memory effect of combining a type-I PRMT inhibitor (MS023) with an anti-programmed cell death protein 1 (PD-1) antibody.

RESULTS

Type-I PRMT inhibition combined with anti-PD-1 therapy reduced tumor growth. Mechanistically, type-I PRMT inhibition reshaped the TME. Increased CD8 T-cell infiltration was verified using flow cytometry. Increased clonotypes and clonal diversity were also observed after MS023 treatment, which contributed to immune memory following combination treatment.

CONCLUSIONS

Targeting type-I PRMT can potentially improve immunotherapeutic efficacies in patients with TNBC. By enhancing the tumor immunogenicity and promoting a more favorable immune microenvironment, this combined approach may enable more patients with TNBC to benefit from immunotherapies.

A real-world observation on thrombopoietic agents for patients with cancer treatment-induced thrombocytopenia in China: A multicenter, cross-sectional study

BACKGROUND

Studies on various thrombopoietic agents for cancer treatment-induced thrombocytopenia (CTIT) in China are lacking. This study aimed to provide detailed clinical profiles to understand the outcomes and safety of different CTIT treatment regimens.

METHODS

In this retrospective, cross-sectional study, 1664 questionnaires were collected from 33 hospitals between March 1 and July 1, 2021. Patients aged >18 years were enrolled who were diagnosed with CTIT and treated with recombinant interleukin 11 (rhIL-11), recombinant thrombopoietin (rhTPO), or a thrombopoietin receptor agonist (TPO-RA). The outcomes, compliance, and safety of different treatments were analyzed.

RESULTS

Among the 1437 analyzable cases, most patients were treated with either rhTPO alone (49.3%) or rhIL-11 alone (27.0%). The most common combination regimen used was rhTPO and rhIL-11 (10.9%). Platelet transfusions were received by 117 cases (8.1%). In multivariate analysis, rhTPO was associated with a significantly lower proportion of platelet recovery, platelet transfusion, and hospitalization due to chemotherapy-induced thrombocytopenia (CIT) than rhIL-11 alone. No significant difference was observed in the time taken to achieve a platelet count of >100 × 109/L and chemotherapy dose reduction due to CIT among the different thrombopoietic agents. The outcomes of thrombocytopenia in 170 patients who received targeted therapy and/or immunotherapy are also summarized. The results show that the proportion of platelet recovery was similar among the different thrombopoietic agents. No new safety signals related to thrombopoietic agents were observed in this study. A higher proportion of physicians preferred to continue treatment with TPO-RA alone than with rhTPO and rhIL-11.

CONCLUSIONS

This survey provides an overview of CTIT and the application of various thrombopoietic agents throughout China. Comparison of monotherapy with rhIL-11, rhTPO, and TPO-RA requires further randomized clinical trials. The appropriate application for thrombopoietic agents should depend on the pretreatment of platelets, treatment variables, and risk of bleeding.

PLAIN LANGUAGE SUMMARY

To provide an overview of the outcome of cancer treatment-induced thrombocytopenia in China, our cross-sectional study analyzed 1437 cases treated with different thrombopoietic agents. Most of the patients were treated with recombinant interleukin 11 (rhIL-11) and recombinant thrombopoietin (rhTPO). rhTPO was associated with a significantly lower proportion of platelet recovery and platelet transfusion compared with rhIL-11.

Cyclin-dependent kinase inhibitors enhance programmed cell death protein 1 immune checkpoint blockade efficacy in triple-negative breast cancer by affecting the immune microenvironment

BACKGROUND

Clinical studies on programmed death-ligand 1 (PD-L1) immune checkpoint inhibitors for treating triple-negative breast cancer (TNBC) have shown unsatisfactory efficacy due to low tumor-infiltrating lymphocyte (TIL) levels. Inhibitors targeting cyclin-dependent kinase (CDK) proteins can affect the immune microenvironment, increase TIL levels, and promote antitumor immunity, thus providing a new direction for TNBC treatment strategies.

METHODS

The authors tested three CDK inhibitors on the TNBC cell lines MDA-MB-231 and 4T1 and validated their antitumor effects and impact on the immune microenvironment using multiple detection methods. They verified the efficacy and immune-related mechanisms of different combination therapy experiments in a 4T1 cell-transplanted BALB/c mouse model.

RESULTS

Treatment with CDK inhibitors for 72 hours inhibited cell proliferation, clone formation, migration, and cell-cycle arrest and induced apoptosis in human breast cancer MDA-MB-231 cells and mouse breast cancer 4T1 cells. CDK inhibitors suppressed DNA methylation by downregulating DNMT1, DNMT3a, and DNMT3b expression. These three inhibitors promoted the secretion of various chemokines, enhanced tumor cell antigen presentation, and increased PD-L1 expression. CDK inhibitors improved the efficacy of immunotherapy in animal models and increased TIL levels.

CONCLUSIONS

Combination therapy with CDK and PD-L1 immune checkpoint inhibitors affects the immune microenvironment, promotes antitumor immunity, and improves the efficacy of immunotherapy for TNBC.

Study of the f_{0}(980) and f_{0}(500) Scalar Mesons through the Decay D_{s}^{+}→π^{+}π^{-}e^{+}ν_{e}

Using e^{+}e^{-} collision data corresponding to an integrated luminosity of 7.33  fb^{-1} recorded by the BESIII detector at center-of-mass energies between 4.128 and 4.226 GeV, we present an analysis of the decay D_{s}^{+}→π^{+}π^{-}e^{+}ν_{e}, where the D_{s}^{+} is produced via the process e^{+}e^{-}→D_{s}^{*±}D_{s}^{∓}. We observe the f_{0}(980) in the π^{+}π^{-} system and the branching fraction of the decay D_{s}^{+}→f_{0}(980)e^{+}ν_{e} with f_{0}(980)→π^{+}π^{-} measured to be (1.72±0.13_{stat}±0.10_{syst})×10^{-3}, where the uncertainties are statistical and systematic, respectively. The dynamics of the D_{s}^{+}→f_{0}(980)e^{+}ν_{e} decay are studied with the simple pole parametrization of the hadronic form factor and the Flatté formula describing the f_{0}(980) in the differential decay rate, and the product of the form factor f_{+}^{f_{0}}(0) and the c→s Cabibbo-Kobayashi-Maskawa matrix element |V_{cs}| is determined for the first time to be f_{+}^{f_{0}}(0)|V_{cs}|=0.504±0.017_{stat}±0.035_{syst}. Furthermore, the decay D_{s}^{+}→f_{0}(500)e^{+}ν_{e} is searched for the first time but no signal is found. The upper limit on the branching fraction of D_{s}^{+}→f_{0}(500)e^{+}ν_{e}, f_{0}(500)→π^{+}π^{-} decay is set to be 3.3×10^{-4} at 90% confidence level.

Proteomic and metabolomic characterization of bone, liver, and lung metastases in plasma of breast cancer patients

BACKGROUND

Breast cancer (BC) is the second leading cause of cancer-related deaths among women, primarily due to metastases to other organs rather than the primary tumor.

METHODS

In this study, a comprehensive analysis of plasma proteomics and metabolomics was conducted on a cohort of 51 BC patients. Potential biomarkers were screened by the Least Absolute Shrinkage and Selection Operator (LASSO) regression and Random Forest algorithm. Additionally, enzyme-linked immunosorbent assay (ELISA) kits and untargeted metabolomics were utilized to validate the prognostic biomarkers in an independent cohort.

RESULTS

In the study, extracellular matrix (ECM)-related functional enrichments were observed to be enriched in BC cases with bone metastases. Proteins dysregulated in retinol metabolism in liver metastases and leukocyte transendothelial migration in lung metastases were also identified. Machine learning models identified specific biomarker panels for each metastasis type, achieving high diagnostic accuracy with area under the curve (AUC) of 0.955 for bone, 0.941 for liver, and 0.989 for lung metastases.

CONCLUSIONS

For bone metastasis, biomarkers such as leucyl-tryptophan, LysoPC(P-16:0/0:0), FN1, and HSPG2 have been validated. dUDP, LPE(18:1/0:0), and aspartylphenylalanine have been confirmed for liver metastasis. For lung metastasis, dUDP, testosterone sulfate, and PE(14:0/20:5) have been established.

Observation of D^{+}→K_{S}^{0}a_{0}(980)^{+} in the Amplitude Analysis of D^{+}→K_{S}^{0}π^{+}η

We perform for the first time an amplitude analysis of the decay D^{+}→K_{S}^{0}π^{+}η and report the observation of the decay D^{+}→K_{S}^{0}a_{0}(980)^{+} using 2.93  fb^{-1} of e^{+}e^{-} collision data taken at a center-of-mass energy of 3.773 GeV with the BESIII detector. As the only W-annihilation-free decay among D to a_{0}(980) pseudoscalar, D^{+}→K_{S}^{0}a_{0}(980)^{+} is the ideal decay in extracting the contributions of the W-emission amplitudes involving a_{0}(980) and to study the final-state interactions. The absolute branching fraction of D^{+}→K_{S}^{0}π^{+}η is measured to be (1.27±0.04_{stat}±0.03_{syst})%. The branching fractions of intermediate processes D^{+}→K_{S}^{0}a_{0}(980)^{+} with a_{0}(980)^{+}→π^{+}η and D^{+}→π^{+}K[over ¯]_{0}^{*}(1430)^{0} with K[over ¯]_{0}^{*}(1430)^{0}→K_{S}^{0}η are measured to be (1.33±0.05_{stat}±0.04_{syst})% and (0.14±0.03_{stat}±0.01_{syst})%, respectively.

Observation of Significant Flavor-SU(3) Breaking in the Kaon Wave Function at 12<Q^{2}<25 GeV^{2} and Discovery of the Charmless Decay ψ(3770)→K_{S}^{0}K_{L}^{0}

We present cross sections for the reaction e^{+}e^{-}→K_{S}^{0}K_{L}^{0} at center-of-mass energies ranging from 3.51 to 4.95 GeV using data samples collected in the BESIII experiment, corresponding to a total integrated luminosity of 26.5  fb^{-1}. The ratio of neutral-to-charged kaon form factors at large momentum transfers (12 Collapse

Key Words Collapse

MESH Headings Collapse

Grants Collapse

Affiliation(s)

M Ablikim Institute of High Energy Physics, Beijing 100049, People's Republic of China
M N Achasov Budker Institute of Nuclear Physics SB RAS (BINP), Novosibirsk 630090, Russia
P Adlarson Uppsala University, Box 516, SE-75120 Uppsala, Sweden
X C Ai Zhengzhou University, Zhengzhou 450001, People's Republic of China
R Aliberti Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
A Amoroso University of Turin and INFN, University of Turin, I-10125 Turin, Italy INFN, I-10125, Turin, Italy
M R An Liaoning Normal University, Dalian 116029, People's Republic of China
Q An State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
Y Bai Southeast University, Nanjing 211100, People's Republic of China
O Bakina Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
I Balossino INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122 Ferrara, Italy
Y Ban Peking University, Beijing 100871, People's Republic of China
H-R Bao University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
V Batozskaya Institute of High Energy Physics, Beijing 100049, People's Republic of China National Centre for Nuclear Research, Warsaw 02-093, Poland
K Begzsuren Institute of Physics and Technology, Peace Avenue 54B, Ulaanbaatar 13330, Mongolia
N Berger Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
M Berlowski National Centre for Nuclear Research, Warsaw 02-093, Poland
M Bertani INFN Laboratori Nazionali di Frascati, INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
D Bettoni INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122 Ferrara, Italy
F Bianchi University of Turin and INFN, University of Turin, I-10125 Turin, Italy INFN, I-10125, Turin, Italy
E Bianco University of Turin and INFN, University of Turin, I-10125 Turin, Italy INFN, I-10125, Turin, Italy
A Bortone University of Turin and INFN, University of Turin, I-10125 Turin, Italy INFN, I-10125, Turin, Italy
I Boyko Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
R A Briere Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
A Brueggemann University of Muenster, Wilhelm-Klemm-Strasse 9, 48149 Muenster, Germany
H Cai Wuhan University, Wuhan 430072, People's Republic of China
X Cai Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
A Calcaterra INFN Laboratori Nazionali di Frascati, INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
G F Cao Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
N Cao Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
S A Cetin Turkish Accelerator Center Particle Factory Group, Istinye University, 34010 Istanbul, Turkey
J F Chang Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
T T Chang Xinyang Normal University, Xinyang 464000, People's Republic of China
W L Chang Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
G R Che Nankai University, Tianjin 300071, People's Republic of China
G Chelkov Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
C Chen Nankai University, Tianjin 300071, People's Republic of China
Chao Chen Soochow University, Suzhou 215006, People's Republic of China
G Chen Institute of High Energy Physics, Beijing 100049, People's Republic of China
H S Chen Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
M L Chen Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
S J Chen Nanjing University, Nanjing 210093, People's Republic of China
S L Chen North China Electric Power University, Beijing 102206, People's Republic of China
S M Chen Tsinghua University, Beijing 100084, People's Republic of China
T Chen Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
X R Chen Institute of Modern Physics, Lanzhou 730000, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
X T Chen Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Y B Chen Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
Y Q Chen Jilin University, Changchun 130012, People's Republic of China
Z J Chen Hunan University, Changsha 410082, People's Republic of China
S K Choi Chung-Ang University, Seoul, 06974, Republic of Korea
X Chu Nankai University, Tianjin 300071, People's Republic of China
G Cibinetto INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122 Ferrara, Italy
S C Coen Bochum Ruhr-University, D-44780 Bochum, Germany
F Cossio INFN, I-10125, Turin, Italy
J J Cui Shandong University, Jinan 250100, People's Republic of China
H L Dai Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
J P Dai Yunnan University, Kunming 650500, People's Republic of China
A Dbeyssi Helmholtz Institute Mainz, Staudinger Weg 18, D-55099 Mainz, Germany
R E de Boer Bochum Ruhr-University, D-44780 Bochum, Germany
D Dedovich Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
Z Y Deng Institute of High Energy Physics, Beijing 100049, People's Republic of China
A Denig Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
I Denysenko Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
M Destefanis University of Turin and INFN, University of Turin, I-10125 Turin, Italy INFN, I-10125, Turin, Italy
F De Mori University of Turin and INFN, University of Turin, I-10125 Turin, Italy INFN, I-10125, Turin, Italy
B Ding Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Jinan, Jinan 250022, People's Republic of China
X X Ding Peking University, Beijing 100871, People's Republic of China
Y Ding Liaoning University, Shenyang 110036, People's Republic of China
Y Ding Jilin University, Changchun 130012, People's Republic of China
J Dong Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
L Y Dong Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
M Y Dong Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
X Dong Wuhan University, Wuhan 430072, People's Republic of China
M C Du Institute of High Energy Physics, Beijing 100049, People's Republic of China
S X Du Zhengzhou University, Zhengzhou 450001, People's Republic of China
Z H Duan Nanjing University, Nanjing 210093, People's Republic of China
P Egorov Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
Y H Fan North China Electric Power University, Beijing 102206, People's Republic of China
J Fang Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
S S Fang Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
W X Fang Institute of High Energy Physics, Beijing 100049, People's Republic of China
Y Fang Institute of High Energy Physics, Beijing 100049, People's Republic of China
Y Q Fang Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
R Farinelli INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122 Ferrara, Italy
L Fava University of Eastern Piedmont, I-15121 Alessandria, Italy INFN, I-10125, Turin, Italy
F Feldbauer Bochum Ruhr-University, D-44780 Bochum, Germany
G Felici INFN Laboratori Nazionali di Frascati, INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
C Q Feng State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
J H Feng Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
K Fischer University of Oxford, Keble Road, Oxford OX13RH, United Kingdom
M Fritsch Bochum Ruhr-University, D-44780 Bochum, Germany
C D Fu Institute of High Energy Physics, Beijing 100049, People's Republic of China
J L Fu University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Y W Fu Institute of High Energy Physics, Beijing 100049, People's Republic of China
H Gao University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Y N Gao Peking University, Beijing 100871, People's Republic of China
Yang Gao State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
S Garbolino INFN, I-10125, Turin, Italy
I Garzia INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122 Ferrara, Italy University of Ferrara, I-44122 Ferrara, Italy
P T Ge Wuhan University, Wuhan 430072, People's Republic of China
Z W Ge Nanjing University, Nanjing 210093, People's Republic of China
C Geng Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
E M Gersabeck University of Manchester, Oxford Road, Manchester, M13 9PL, United Kingdom
A Gilman University of Oxford, Keble Road, Oxford OX13RH, United Kingdom
K Goetzen GSI Helmholtzcentre for Heavy Ion Research GmbH, D-64291 Darmstadt, Germany
L Gong Liaoning University, Shenyang 110036, People's Republic of China
W X Gong Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
W Gradl Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
S Gramigna INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122 Ferrara, Italy University of Ferrara, I-44122 Ferrara, Italy
M Greco University of Turin and INFN, University of Turin, I-10125 Turin, Italy INFN, I-10125, Turin, Italy
M H Gu Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
Y T Gu Guangxi University, Nanning 530004, People's Republic of China
C Y Guan Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Z L Guan Henan University of Technology, Zhengzhou 450001, People's Republic of China
A Q Guo Institute of Modern Physics, Lanzhou 730000, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
L B Guo Nanjing Normal University, Nanjing 210023, People's Republic of China
M J Guo Shandong University, Jinan 250100, People's Republic of China
R P Guo Shandong Normal University, Jinan 250014, People's Republic of China
Y P Guo Fudan University, Shanghai 200433, People's Republic of China
A Guskov Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
J Gutierrez Indiana University, Bloomington, Indiana 47405, USA
T T Han Institute of High Energy Physics, Beijing 100049, People's Republic of China
W Y Han Liaoning Normal University, Dalian 116029, People's Republic of China
X Q Hao Henan Normal University, Xinxiang 453007, People's Republic of China
F A Harris University of Hawaii, Honolulu, Hawaii 96822, USA
K K He Soochow University, Suzhou 215006, People's Republic of China
K L He Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
F H H Heinsius Bochum Ruhr-University, D-44780 Bochum, Germany
C H Heinz Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
Y K Heng Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
C Herold Suranaree University of Technology, University Avenue 111, Nakhon Ratchasima 30000, Thailand
T Holtmann Bochum Ruhr-University, D-44780 Bochum, Germany
P C Hong Fudan University, Shanghai 200433, People's Republic of China
G Y Hou Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
X T Hou Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Y R Hou University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Z L Hou Institute of High Energy Physics, Beijing 100049, People's Republic of China
B Y Hu Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
H M Hu Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
J F Hu South China Normal University, Guangzhou 510006, People's Republic of China
T Hu Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Y Hu Institute of High Energy Physics, Beijing 100049, People's Republic of China
G S Huang State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
K X Huang Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
L Q Huang Institute of Modern Physics, Lanzhou 730000, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
X T Huang Shandong University, Jinan 250100, People's Republic of China
Y P Huang Institute of High Energy Physics, Beijing 100049, People's Republic of China
T Hussain University of the Punjab, Lahore-54590, Pakistan
N Hüsken Indiana University, Bloomington, Indiana 47405, USA Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
N In der Wiesche University of Muenster, Wilhelm-Klemm-Strasse 9, 48149 Muenster, Germany
M Irshad State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
J Jackson Indiana University, Bloomington, Indiana 47405, USA
S Jaeger Bochum Ruhr-University, D-44780 Bochum, Germany
S Janchiv Institute of Physics and Technology, Peace Avenue 54B, Ulaanbaatar 13330, Mongolia
J H Jeong Chung-Ang University, Seoul, 06974, Republic of Korea
Q Ji Institute of High Energy Physics, Beijing 100049, People's Republic of China
Q P Ji Henan Normal University, Xinxiang 453007, People's Republic of China
X B Ji Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
X L Ji Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
Y Y Ji Shandong University, Jinan 250100, People's Republic of China
X Q Jia Shandong University, Jinan 250100, People's Republic of China
Z K Jia State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
H J Jiang Wuhan University, Wuhan 430072, People's Republic of China
P C Jiang Peking University, Beijing 100871, People's Republic of China
S S Jiang Liaoning Normal University, Dalian 116029, People's Republic of China
T J Jiang Hangzhou Normal University, Hangzhou 310036, People's Republic of China
X S Jiang Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Y Jiang University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
J B Jiao Shandong University, Jinan 250100, People's Republic of China
Z Jiao Huangshan College, Huangshan 245000, People's Republic of China
S Jin Nanjing University, Nanjing 210093, People's Republic of China
Y Jin University of Jinan, Jinan 250022, People's Republic of China
M Q Jing Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
X M Jing University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
T Johansson Uppsala University, Box 516, SE-75120 Uppsala, Sweden
X Kui Institute of High Energy Physics, Beijing 100049, People's Republic of China
S Kabana Instituto de Alta Investigación, Universidad de Tarapacá, Casilla 7D, Arica 1000000, Chile
N Kalantar-Nayestanaki University of Groningen, NL-9747 AA Groningen, The Netherlands
X L Kang China University of Geosciences, Wuhan 430074, People's Republic of China
X S Kang Liaoning University, Shenyang 110036, People's Republic of China
M Kavatsyuk University of Groningen, NL-9747 AA Groningen, The Netherlands
B C Ke Zhengzhou University, Zhengzhou 450001, People's Republic of China
V Khachatryan Indiana University, Bloomington, Indiana 47405, USA
A Khoukaz University of Muenster, Wilhelm-Klemm-Strasse 9, 48149 Muenster, Germany
R Kiuchi Institute of High Energy Physics, Beijing 100049, People's Republic of China
R Kliemt GSI Helmholtzcentre for Heavy Ion Research GmbH, D-64291 Darmstadt, Germany
O B Kolcu Turkish Accelerator Center Particle Factory Group, Istinye University, 34010 Istanbul, Turkey
B Kopf Bochum Ruhr-University, D-44780 Bochum, Germany
M Kuessner Bochum Ruhr-University, D-44780 Bochum, Germany
A Kupsc National Centre for Nuclear Research, Warsaw 02-093, Poland Uppsala University, Box 516, SE-75120 Uppsala, Sweden
W Kühn Justus-Liebig-Universitaet Giessen, II. Physikalisches Institut, Heinrich-Buff-Ring 16, D-35392 Giessen, Germany
J J Lane University of Manchester, Oxford Road, Manchester, M13 9PL, United Kingdom
P Larin Helmholtz Institute Mainz, Staudinger Weg 18, D-55099 Mainz, Germany
A Lavania Indian Institute of Technology Madras, Chennai 600036, India
L Lavezzi University of Turin and INFN, University of Turin, I-10125 Turin, Italy INFN, I-10125, Turin, Italy
T T Lei State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
Z H Lei State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
H Leithoff Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
M Lellmann Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
T Lenz Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
C Li Qufu Normal University, Qufu 273165, People's Republic of China
C Li Nankai University, Tianjin 300071, People's Republic of China
C H Li Liaoning Normal University, Dalian 116029, People's Republic of China
Cheng Li State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
D M Li Zhengzhou University, Zhengzhou 450001, People's Republic of China
F Li Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
G Li Institute of High Energy Physics, Beijing 100049, People's Republic of China
H Li State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
H B Li Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
H J Li Henan Normal University, Xinxiang 453007, People's Republic of China
H N Li South China Normal University, Guangzhou 510006, People's Republic of China
Hui Li Nankai University, Tianjin 300071, People's Republic of China
J R Li Tsinghua University, Beijing 100084, People's Republic of China
J S Li Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
J W Li Shandong University, Jinan 250100, People's Republic of China
Ke Li Institute of High Energy Physics, Beijing 100049, People's Republic of China
L J Li Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
L K Li Institute of High Energy Physics, Beijing 100049, People's Republic of China
Lei Li Renmin University of China, Beijing 100872, People's Republic of China
M H Li Nankai University, Tianjin 300071, People's Republic of China
P R Li Lanzhou University, Lanzhou 730000, People's Republic of China
Q X Li Shandong University, Jinan 250100, People's Republic of China
S X Li Fudan University, Shanghai 200433, People's Republic of China
T Li Shandong University, Jinan 250100, People's Republic of China
W D Li Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
W G Li Institute of High Energy Physics, Beijing 100049, People's Republic of China
X H Li State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
X L Li Shandong University, Jinan 250100, People's Republic of China
Xiaoyu Li Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Y G Li Peking University, Beijing 100871, People's Republic of China
Z J Li Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
Z X Li Guangxi University, Nanning 530004, People's Republic of China
C Liang Nanjing University, Nanjing 210093, People's Republic of China
H Liang Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
H Liang State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
Y F Liang Sichuan University, Chengdu 610064, People's Republic of China
Y T Liang Institute of Modern Physics, Lanzhou 730000, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
G R Liao Guangxi Normal University, Guilin 541004, People's Republic of China
L Z Liao Shandong University, Jinan 250100, People's Republic of China
Y P Liao Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
J Libby Indian Institute of Technology Madras, Chennai 600036, India
A Limphirat Suranaree University of Technology, University Avenue 111, Nakhon Ratchasima 30000, Thailand
D X Lin Institute of Modern Physics, Lanzhou 730000, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
T Lin Institute of High Energy Physics, Beijing 100049, People's Republic of China
B J Liu Institute of High Energy Physics, Beijing 100049, People's Republic of China
B X Liu Wuhan University, Wuhan 430072, People's Republic of China
C Liu Jilin University, Changchun 130012, People's Republic of China
C X Liu Institute of High Energy Physics, Beijing 100049, People's Republic of China
F H Liu Shanxi University, Taiyuan 030006, People's Republic of China
Fang Liu Institute of High Energy Physics, Beijing 100049, People's Republic of China
Feng Liu Central China Normal University, Wuhan 430079, People's Republic of China
G M Liu South China Normal University, Guangzhou 510006, People's Republic of China
H Liu Lanzhou University, Lanzhou 730000, People's Republic of China
H B Liu Guangxi University, Nanning 530004, People's Republic of China
H M Liu Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Huanhuan Liu Institute of High Energy Physics, Beijing 100049, People's Republic of China
Huihui Liu Henan University of Science and Technology, Luoyang 471003, People's Republic of China
J B Liu State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
J Y Liu Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
K Liu Institute of High Energy Physics, Beijing 100049, People's Republic of China
K Y Liu Liaoning University, Shenyang 110036, People's Republic of China
Ke Liu Henan University of Technology, Zhengzhou 450001, People's Republic of China
L Liu State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
L C Liu Nankai University, Tianjin 300071, People's Republic of China
Lu Liu Nankai University, Tianjin 300071, People's Republic of China
M H Liu Fudan University, Shanghai 200433, People's Republic of China
P L Liu Institute of High Energy Physics, Beijing 100049, People's Republic of China
Q Liu University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
S B Liu State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
T Liu Fudan University, Shanghai 200433, People's Republic of China
W K Liu Nankai University, Tianjin 300071, People's Republic of China
W M Liu State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
X Liu Lanzhou University, Lanzhou 730000, People's Republic of China
Y Liu Lanzhou University, Lanzhou 730000, People's Republic of China
Y Liu Zhengzhou University, Zhengzhou 450001, People's Republic of China
Y B Liu Nankai University, Tianjin 300071, People's Republic of China
Z A Liu Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Z Q Liu Shandong University, Jinan 250100, People's Republic of China
X C Lou Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
F X Lu Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
H J Lu Huangshan College, Huangshan 245000, People's Republic of China
J G Lu Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
X L Lu Institute of High Energy Physics, Beijing 100049, People's Republic of China
Y Lu Central South University, Changsha 410083, People's Republic of China
Y P Lu Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
Z H Lu Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
C L Luo Nanjing Normal University, Nanjing 210023, People's Republic of China
M X Luo Zhejiang University, Hangzhou 310027, People's Republic of China
T Luo Fudan University, Shanghai 200433, People's Republic of China
X L Luo Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
X R Lyu University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Y F Lyu Nankai University, Tianjin 300071, People's Republic of China
F C Ma Liaoning University, Shenyang 110036, People's Republic of China
H Ma Yunnan University, Kunming 650500, People's Republic of China
H L Ma Institute of High Energy Physics, Beijing 100049, People's Republic of China
J L Ma Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
L L Ma Shandong University, Jinan 250100, People's Republic of China
M M Ma Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Q M Ma Institute of High Energy Physics, Beijing 100049, People's Republic of China
R Q Ma Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
X Y Ma Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
Y Ma Peking University, Beijing 100871, People's Republic of China
Y M Ma Institute of Modern Physics, Lanzhou 730000, People's Republic of China
F E Maas Helmholtz Institute Mainz, Staudinger Weg 18, D-55099 Mainz, Germany
M Maggiora University of Turin and INFN, University of Turin, I-10125 Turin, Italy INFN, I-10125, Turin, Italy
S Malde University of Oxford, Keble Road, Oxford OX13RH, United Kingdom
Q A Malik University of the Punjab, Lahore-54590, Pakistan
A Mangoni INFN Sezione di Perugia, I-06100 Perugia, Italy
Y J Mao Peking University, Beijing 100871, People's Republic of China
Z P Mao Institute of High Energy Physics, Beijing 100049, People's Republic of China
S Marcello University of Turin and INFN, University of Turin, I-10125 Turin, Italy INFN, I-10125, Turin, Italy
Z X Meng University of Jinan, Jinan 250022, People's Republic of China
J G Messchendorp GSI Helmholtzcentre for Heavy Ion Research GmbH, D-64291 Darmstadt, Germany University of Groningen, NL-9747 AA Groningen, The Netherlands
G Mezzadri INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122 Ferrara, Italy
H Miao Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
T J Min Nanjing University, Nanjing 210093, People's Republic of China
R E Mitchell Indiana University, Bloomington, Indiana 47405, USA
X H Mo Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
B Moses Indiana University, Bloomington, Indiana 47405, USA
N Yu Muchnoi Budker Institute of Nuclear Physics SB RAS (BINP), Novosibirsk 630090, Russia
J Muskalla Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
Y Nefedov Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
F Nerling Helmholtz Institute Mainz, Staudinger Weg 18, D-55099 Mainz, Germany
I B Nikolaev Budker Institute of Nuclear Physics SB RAS (BINP), Novosibirsk 630090, Russia
Z Ning Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
S Nisar COMSATS University Islamabad, Lahore Campus, Defence Road, Off Raiwind Road, 54000 Lahore, Pakistan
Q L Niu Lanzhou University, Lanzhou 730000, People's Republic of China
W D Niu Soochow University, Suzhou 215006, People's Republic of China
Y Niu Shandong University, Jinan 250100, People's Republic of China
S L Olsen University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Q Ouyang Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
S Pacetti INFN Sezione di Perugia, I-06100 Perugia, Italy University of Perugia, I-06100 Perugia, Italy
X Pan Soochow University, Suzhou 215006, People's Republic of China
Y Pan Southeast University, Nanjing 211100, People's Republic of China
A Pathak Jilin University, Changchun 130012, People's Republic of China
P Patteri INFN Laboratori Nazionali di Frascati, INFN Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
Y P Pei State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
M Pelizaeus Bochum Ruhr-University, D-44780 Bochum, Germany
H P Peng State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
Y Y Peng Lanzhou University, Lanzhou 730000, People's Republic of China
K Peters GSI Helmholtzcentre for Heavy Ion Research GmbH, D-64291 Darmstadt, Germany
J L Ping Nanjing Normal University, Nanjing 210023, People's Republic of China
R G Ping Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
S Plura Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
V Prasad Instituto de Alta Investigación, Universidad de Tarapacá, Casilla 7D, Arica 1000000, Chile
F Z Qi Institute of High Energy Physics, Beijing 100049, People's Republic of China
H Qi State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
H R Qi Tsinghua University, Beijing 100084, People's Republic of China
M Qi Nanjing University, Nanjing 210093, People's Republic of China
T Y Qi Fudan University, Shanghai 200433, People's Republic of China
S Qian Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
W B Qian University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
C F Qiao University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
J J Qin University of South China, Hengyang 421001, People's Republic of China
L Q Qin Guangxi Normal University, Guilin 541004, People's Republic of China
X S Qin Shandong University, Jinan 250100, People's Republic of China
Z H Qin Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
J F Qiu Institute of High Energy Physics, Beijing 100049, People's Republic of China
S Q Qu Tsinghua University, Beijing 100084, People's Republic of China
C F Redmer Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
K J Ren Liaoning Normal University, Dalian 116029, People's Republic of China
A Rivetti INFN, I-10125, Turin, Italy
M Rolo INFN, I-10125, Turin, Italy
G Rong Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Ch Rosner Helmholtz Institute Mainz, Staudinger Weg 18, D-55099 Mainz, Germany
S N Ruan Nankai University, Tianjin 300071, People's Republic of China
N Salone National Centre for Nuclear Research, Warsaw 02-093, Poland
A Sarantsev Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
Y Schelhaas Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
K Schoenning Uppsala University, Box 516, SE-75120 Uppsala, Sweden
M Scodeggio INFN Sezione di Ferrara, INFN Sezione di Ferrara, I-44122 Ferrara, Italy University of Ferrara, I-44122 Ferrara, Italy
K Y Shan Fudan University, Shanghai 200433, People's Republic of China
W Shan Hunan Normal University, Changsha 410081, People's Republic of China
X Y Shan State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
J F Shangguan Soochow University, Suzhou 215006, People's Republic of China
L G Shao Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
M Shao State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
C P Shen Fudan University, Shanghai 200433, People's Republic of China
H F Shen Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
W H Shen University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
X Y Shen Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
B A Shi University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
H C Shi State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
J L Shi Fudan University, Shanghai 200433, People's Republic of China
J Y Shi Institute of High Energy Physics, Beijing 100049, People's Republic of China
Q Q Shi Soochow University, Suzhou 215006, People's Republic of China
R S Shi Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
X Shi Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
J J Song Henan Normal University, Xinxiang 453007, People's Republic of China
T Z Song Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
W M Song Institute of High Energy Physics, Beijing 100049, People's Republic of China Jilin University, Changchun 130012, People's Republic of China
Y J Song Fudan University, Shanghai 200433, People's Republic of China
Y X Song Peking University, Beijing 100871, People's Republic of China
S Sosio University of Turin and INFN, University of Turin, I-10125 Turin, Italy INFN, I-10125, Turin, Italy
S Spataro University of Turin and INFN, University of Turin, I-10125 Turin, Italy INFN, I-10125, Turin, Italy
F Stieler Johannes Gutenberg University of Mainz, Johann-Joachim-Becher-Weg 45, D-55099 Mainz, Germany
Y J Su University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
G B Sun Wuhan University, Wuhan 430072, People's Republic of China
G X Sun Institute of High Energy Physics, Beijing 100049, People's Republic of China
H Sun University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
H K Sun Institute of High Energy Physics, Beijing 100049, People's Republic of China
J F Sun Henan Normal University, Xinxiang 453007, People's Republic of China
K Sun Tsinghua University, Beijing 100084, People's Republic of China
L Sun Wuhan University, Wuhan 430072, People's Republic of China
S S Sun Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
T Sun Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China
W Y Sun Jilin University, Changchun 130012, People's Republic of China
Y Sun China University of Geosciences, Wuhan 430074, People's Republic of China
Y J Sun State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
Y Z Sun Institute of High Energy Physics, Beijing 100049, People's Republic of China
Z T Sun Shandong University, Jinan 250100, People's Republic of China
Y X Tan State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
C J Tang Sichuan University, Chengdu 610064, People's Republic of China
G Y Tang Institute of High Energy Physics, Beijing 100049, People's Republic of China
J Tang Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
Y A Tang Wuhan University, Wuhan 430072, People's Republic of China
L Y Tao University of South China, Hengyang 421001, People's Republic of China
Q T Tao Hunan University, Changsha 410082, People's Republic of China
M Tat University of Oxford, Keble Road, Oxford OX13RH, United Kingdom
J X Teng State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
V Thoren Uppsala University, Box 516, SE-75120 Uppsala, Sweden
W H Tian Shanxi Normal University, Linfen 041004, People's Republic of China
W H Tian Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
Y Tian Institute of Modern Physics, Lanzhou 730000, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Z F Tian Wuhan University, Wuhan 430072, People's Republic of China
I Uman Near East University, Nicosia, North Cyprus, 99138, Mersin 10, Turkey
Y Wan Soochow University, Suzhou 215006, People's Republic of China
S J Wang Shandong University, Jinan 250100, People's Republic of China
B Wang Institute of High Energy Physics, Beijing 100049, People's Republic of China
B L Wang University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Bo Wang State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
C W Wang Nanjing University, Nanjing 210093, People's Republic of China
D Y Wang Peking University, Beijing 100871, People's Republic of China
F Wang University of South China, Hengyang 421001, People's Republic of China
H J Wang Lanzhou University, Lanzhou 730000, People's Republic of China
J P Wang Shandong University, Jinan 250100, People's Republic of China
K Wang Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
L L Wang Institute of High Energy Physics, Beijing 100049, People's Republic of China
M Wang Shandong University, Jinan 250100, People's Republic of China
Meng Wang Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
N Y Wang University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
S Wang Fudan University, Shanghai 200433, People's Republic of China
S Wang Lanzhou University, Lanzhou 730000, People's Republic of China
T Wang Fudan University, Shanghai 200433, People's Republic of China
T J Wang Nankai University, Tianjin 300071, People's Republic of China
W Wang Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
W Wang University of South China, Hengyang 421001, People's Republic of China
W P Wang State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
X Wang Peking University, Beijing 100871, People's Republic of China
X F Wang Lanzhou University, Lanzhou 730000, People's Republic of China
X J Wang Liaoning Normal University, Dalian 116029, People's Republic of China
X L Wang Fudan University, Shanghai 200433, People's Republic of China
Y Wang Tsinghua University, Beijing 100084, People's Republic of China
Y D Wang North China Electric Power University, Beijing 102206, People's Republic of China
Y F Wang Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Y L Wang Henan Normal University, Xinxiang 453007, People's Republic of China
Y N Wang North China Electric Power University, Beijing 102206, People's Republic of China
Y Q Wang Institute of High Energy Physics, Beijing 100049, People's Republic of China
Yaqian Wang Institute of High Energy Physics, Beijing 100049, People's Republic of China Hebei University, Baoding 071002, People's Republic of China
Yi Wang Tsinghua University, Beijing 100084, People's Republic of China
Z Wang Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
Z L Wang University of South China, Hengyang 421001, People's Republic of China
Z Y Wang Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Ziyi Wang University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
D Wei University of Science and Technology Liaoning, Anshan 114051, People's Republic of China
D H Wei Guangxi Normal University, Guilin 541004, People's Republic of China
F Weidner University of Muenster, Wilhelm-Klemm-Strasse 9, 48149 Muenster, Germany
S P Wen Institute of High Energy Physics, Beijing 100049, People's Republic of China
C W Wenzel Bochum Ruhr-University, D-44780 Bochum, Germany
U Wiedner Bochum Ruhr-University, D-44780 Bochum, Germany
G Wilkinson University of Oxford, Keble Road, Oxford OX13RH, United Kingdom
M Wolke Uppsala University, Box 516, SE-75120 Uppsala, Sweden
L Wollenberg Bochum Ruhr-University, D-44780 Bochum, Germany
C Wu Liaoning Normal University, Dalian 116029, People's Republic of China
J F Wu Institute of High Energy Physics, Beijing 100049, People's Republic of China China Center of Advanced Science and Technology, Beijing 100190, People's Republic of China
L H Wu Institute of High Energy Physics, Beijing 100049, People's Republic of China
L J Wu Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
X Wu Fudan University, Shanghai 200433, People's Republic of China
X H Wu Jilin University, Changchun 130012, People's Republic of China
Y Wu University of Science and Technology of China, Hefei 230026, People's Republic of China
Y H Wu Soochow University, Suzhou 215006, People's Republic of China
Y J Wu Institute of Modern Physics, Lanzhou 730000, People's Republic of China
Z Wu Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
L Xia State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
X M Xian Liaoning Normal University, Dalian 116029, People's Republic of China
T Xiang Peking University, Beijing 100871, People's Republic of China
D Xiao Lanzhou University, Lanzhou 730000, People's Republic of China
G Y Xiao Nanjing University, Nanjing 210093, People's Republic of China
S Y Xiao Institute of High Energy Physics, Beijing 100049, People's Republic of China
Y L Xiao Fudan University, Shanghai 200433, People's Republic of China
Z J Xiao Nanjing Normal University, Nanjing 210023, People's Republic of China
C Xie Nanjing University, Nanjing 210093, People's Republic of China
X H Xie Peking University, Beijing 100871, People's Republic of China
Y Xie Shandong University, Jinan 250100, People's Republic of China
Y G Xie Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
Y H Xie Central China Normal University, Wuhan 430079, People's Republic of China
Z P Xie State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
T Y Xing Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
C F Xu Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
C J Xu Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
G F Xu Institute of High Energy Physics, Beijing 100049, People's Republic of China
H Y Xu University of Jinan, Jinan 250022, People's Republic of China
Q J Xu Hangzhou Normal University, Hangzhou 310036, People's Republic of China
Q N Xu Inner Mongolia University, Hohhot 010021, People's Republic of China
W Xu Institute of High Energy Physics, Beijing 100049, People's Republic of China
W L Xu University of Jinan, Jinan 250022, People's Republic of China
X P Xu Soochow University, Suzhou 215006, People's Republic of China
Y C Xu Yantai University, Yantai 264005, People's Republic of China
Z P Xu Nanjing University, Nanjing 210093, People's Republic of China
Z S Xu University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
F Yan Fudan University, Shanghai 200433, People's Republic of China
L Yan Fudan University, Shanghai 200433, People's Republic of China
W B Yan State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
W C Yan Zhengzhou University, Zhengzhou 450001, People's Republic of China
X Q Yan Institute of High Energy Physics, Beijing 100049, People's Republic of China
H J Yang Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China
H L Yang Jilin University, Changchun 130012, People's Republic of China
H X Yang Institute of High Energy Physics, Beijing 100049, People's Republic of China
Tao Yang Institute of High Energy Physics, Beijing 100049, People's Republic of China
Y Yang Fudan University, Shanghai 200433, People's Republic of China
Y F Yang Nankai University, Tianjin 300071, People's Republic of China
Y X Yang Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Yifan Yang Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Z W Yang Lanzhou University, Lanzhou 730000, People's Republic of China
Z P Yao Shandong University, Jinan 250100, People's Republic of China
M Ye Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
M H Ye China Center of Advanced Science and Technology, Beijing 100190, People's Republic of China
J H Yin Institute of High Energy Physics, Beijing 100049, People's Republic of China
Z Y You Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
B X Yu Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
C X Yu Nankai University, Tianjin 300071, People's Republic of China
G Yu Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
J S Yu Hunan University, Changsha 410082, People's Republic of China
T Yu University of South China, Hengyang 421001, People's Republic of China
X D Yu Peking University, Beijing 100871, People's Republic of China
C Z Yuan Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
L Yuan Beihang University, Beijing 100191, People's Republic of China
S C Yuan Institute of High Energy Physics, Beijing 100049, People's Republic of China
Y Yuan Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Z Y Yuan Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
C X Yue Liaoning Normal University, Dalian 116029, People's Republic of China
A A Zafar University of the Punjab, Lahore-54590, Pakistan
F R Zeng Shandong University, Jinan 250100, People's Republic of China
S H Zeng University of South China, Hengyang 421001, People's Republic of China
X Zeng Fudan University, Shanghai 200433, People's Republic of China
Y Zeng Hunan University, Changsha 410082, People's Republic of China
Y J Zeng Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
X Y Zhai Jilin University, Changchun 130012, People's Republic of China
Y C Zhai Shandong University, Jinan 250100, People's Republic of China
Y H Zhan Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
A Q Zhang Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
B L Zhang Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
B X Zhang Institute of High Energy Physics, Beijing 100049, People's Republic of China
D H Zhang Nankai University, Tianjin 300071, People's Republic of China
G Y Zhang Henan Normal University, Xinxiang 453007, People's Republic of China
H Zhang University of Science and Technology of China, Hefei 230026, People's Republic of China
H C Zhang Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
H H Zhang Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
H H Zhang Jilin University, Changchun 130012, People's Republic of China
H Q Zhang Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
H Y Zhang Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
J Zhang Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
J Zhang Zhengzhou University, Zhengzhou 450001, People's Republic of China
J J Zhang Shanxi Normal University, Linfen 041004, People's Republic of China
J L Zhang Henan University, Kaifeng 475004, People's Republic of China
J Q Zhang Nanjing Normal University, Nanjing 210023, People's Republic of China
J W Zhang Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
J X Zhang Lanzhou University, Lanzhou 730000, People's Republic of China
J Y Zhang Institute of High Energy Physics, Beijing 100049, People's Republic of China
J Z Zhang Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Jianyu Zhang University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
L M Zhang Tsinghua University, Beijing 100084, People's Republic of China
L Q Zhang Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
Lei Zhang Nanjing University, Nanjing 210093, People's Republic of China
P Zhang Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Q Y Zhang Liaoning Normal University, Dalian 116029, People's Republic of China Zhengzhou University, Zhengzhou 450001, People's Republic of China
Shuihan Zhang Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Shulei Zhang Hunan University, Changsha 410082, People's Republic of China
X D Zhang North China Electric Power University, Beijing 102206, People's Republic of China
X M Zhang Institute of High Energy Physics, Beijing 100049, People's Republic of China
X Y Zhang Shandong University, Jinan 250100, People's Republic of China
Y Zhang University of South China, Hengyang 421001, People's Republic of China
Y Zhang University of Oxford, Keble Road, Oxford OX13RH, United Kingdom
Y T Zhang Zhengzhou University, Zhengzhou 450001, People's Republic of China
Y H Zhang Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
Yan Zhang State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
Yao Zhang Institute of High Energy Physics, Beijing 100049, People's Republic of China
Z D Zhang Institute of High Energy Physics, Beijing 100049, People's Republic of China
Z H Zhang Institute of High Energy Physics, Beijing 100049, People's Republic of China
Z L Zhang Jilin University, Changchun 130012, People's Republic of China
Z Y Zhang Nankai University, Tianjin 300071, People's Republic of China
Z Y Zhang Wuhan University, Wuhan 430072, People's Republic of China
G Zhao Institute of High Energy Physics, Beijing 100049, People's Republic of China
J Y Zhao Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
J Z Zhao Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
Lei Zhao State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
Ling Zhao Institute of High Energy Physics, Beijing 100049, People's Republic of China
M G Zhao Nankai University, Tianjin 300071, People's Republic of China
R P Zhao University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
S J Zhao Zhengzhou University, Zhengzhou 450001, People's Republic of China
Y B Zhao Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
Y X Zhao Institute of Modern Physics, Lanzhou 730000, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Z G Zhao State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
A Zhemchugov Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
B Zheng University of South China, Hengyang 421001, People's Republic of China
J P Zheng Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China
W J Zheng Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
Y H Zheng University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
B Zhong Nanjing Normal University, Nanjing 210023, People's Republic of China
X Zhong Sun Yat-Sen University, Guangzhou 510275, People's Republic of China
H Zhou Shandong University, Jinan 250100, People's Republic of China
L P Zhou Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
X Zhou Wuhan University, Wuhan 430072, People's Republic of China
X K Zhou Central China Normal University, Wuhan 430079, People's Republic of China
X R Zhou State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
X Y Zhou Liaoning Normal University, Dalian 116029, People's Republic of China
Y Z Zhou Fudan University, Shanghai 200433, People's Republic of China
J Zhu Nankai University, Tianjin 300071, People's Republic of China
K Zhu Institute of High Energy Physics, Beijing 100049, People's Republic of China
K J Zhu Institute of High Energy Physics, Beijing 100049, People's Republic of China State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
L Zhu Jilin University, Changchun 130012, People's Republic of China
L X Zhu University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
S H Zhu University of Science and Technology Liaoning, Anshan 114051, People's Republic of China
S Q Zhu Nanjing University, Nanjing 210093, People's Republic of China
T J Zhu Fudan University, Shanghai 200433, People's Republic of China
W J Zhu Fudan University, Shanghai 200433, People's Republic of China
Y C Zhu State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China
Z A Zhu Institute of High Energy Physics, Beijing 100049, People's Republic of China University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China
J H Zou Institute of High Energy Physics, Beijing 100049, People's Republic of China
J Zu State Key Laboratory of Particle Detection and Electronics, Beijing 100049, Hefei 230026, People's Republic of China University of Science and Technology of China, Hefei 230026, People's Republic of China

Collapse

The complete mitochondrial genome of Tauraco livingstonii (Musophagidae: Tauraco)

Livingstone's turaco, Tauraco livingstonii, belongs to the family Musophagidae. In this study, we obtained the complete mitochondrial genome sequence of Livingstone's turaco by high-throughput sequencing technology and constructed a phylogenetic tree. It was found that the mitochondria of this species are 19,015 bp in length and contain a total of 37 genes, comprising 13 protein-coding genes, 22 tRNA genes, and 2 rRNA genes. The base composition of the mitochondrial genome is 31.61% A, 24.22% T, 30.64% C, and 13.52% G, with a GC content of 44%. Notably, an intriguing phenomenon of mitochondrial genome rearrangements was observed, characterized by the duplication of the tRNA Glu-L-CR gene order. In addition, the results of the phylogenetic tree analysis shed light on the taxonomic position of Livingstone's turaco and supported the taxonomy of Otidimorphae. The study provides a basis for future phylogenetic and taxonomic investigations of Musophagiformes.

[Effect and mechanism of human adipose-derived stem cell exosomes on diabetic peripheral neuropathy]

Objective: To investigate the changes of artemin protein expression in diabetic peripheral neuropathy (DPN) and to explore the regulatory effect of human adipose-derived stem cell (ADSC) exosomes on the change of artemin protein expression. Methods: This research was a prospective observational clinical research combined with experimental research. Thirteen DPN patients (9 males and 4 females, aged 32 to 68 years) who were admitted to the First Affiliated Hospital of Air Force Medical University (hereinafter referred to as our hospital) from May 2022 to October 2023 and met the inclusion criteria were selected as DPN group, and 5 non-diabetes patients (4 males and 1 female, aged 29 to 61 years) who were admitted to our hospital in the same period of time and met the inclusion criteria were selected as control group. The toe nerve or sural nerve tissue in the abandoned tissue after debridement or amputation of patients in the two groups was collected. The pathological changes of nerve tissue were observed after hematoxylin-eosin staining; the protein expressions of S100β and artemin in nerve tissue were observed after immunofluorescence staining, and the artemin protein expression was quantified; the protein and mRNA expressions of artemin were detected by Western blotting and real-time fluorescent quantitative reverse transcription polymerase chain reaction, respectively (the sample number in DPN group and control group was 13 and 5, respectively). Twelve male C57BL/6 mice aged 3 to 5 days were collected to isolate Schwann cells, and the cells were divided into conventional culture group cultured routinely, high glucose alone group (cultured with high concentration of glucose solution only), and high glucose+exosome group (cultured with high concentration of glucose solution and extracted human ADSC exosomes). After 24 hours of culture, the cell proliferation activity was detected by cell counting kit 8 (n=6). After 48 hours of culture, the protein expression of artemin was detected by Western blotting (n=3). Results: Compared with those in control group, the neural supporting cells decreased and the inflammatory cells increased in the nerve tissue of patients in DPN group, showing typical manifestations of nerve injury. Immunofluorescence staining showed that compared with those in control group, the nuclei was more, and the protein expression of S100β was lower in nerve tissue of patients in DPN group. The protein expression of artemin in nerve tissue of patients in DPN group was 71±31, which was significantly lower than 1 729±62 in control group (t=76.92, P<0.05). Western blotting detection showed that the protein expression of artemin in nerve tissue of patients in DPN group was 0.74±0.08, which was significantly lower than 0.97±0.06 in control group (t=5.49, P<0.05). The artemin mRNA expression in nerve tissue of patients in DPN group was significantly lower than that in control group (t=7.65, P<0.05). After 24 hours of culture, compared with that in conventional culture group, the proliferation activities of Schwann cells in high glucose alone group and high glucose+exosome group were significantly decreased (P<0.05); compared with that in high glucose alone group, the proliferation activity of Schwann cells in high glucose+exosome group was significantly increased (P<0.05). After 48 hours of culture, compared with those in conventional culture group, the protein expressions of artemin of Schwann cells in high glucose alone group and high glucose+exosome group were significantly decreased (P<0.05); compared with that in high glucose alone group, the protein expression of artemin of Schwann cells in high glucose+exosome group was significantly increased (P<0.05). Conclusions: The protein expression of artemin in nerve tissue of DPN patients is lower than that in normal nerve tissue, which may be related to the reduction of proliferation activity of Schwann cells by high glucose. Human ADSC exosomes may improve the proliferation activity of Schwann cells by increasing artemin protein expression, thereby delaying the progression of DPN.

Genistein prevents the production of hypospadias induced by Di-(2-ethylhexyl) phthalate through androgen signaling and antioxidant response in rats

Environmental estrogen exposure has increased dramatically over the past 50 years. In particular, prenatal exposure to estrogen causes many congenital diseases, among which reproductive system development disorders are extremely serious. In this study, the molecular mechanism of hypospadias and the therapeutic effect of genistein (GEN) were investigated through in vivo models prepared by Di-(2-ethylhexyl) phthalate (DEHP) exposure between 12 and 19 days of gestation. With increased DEHP concentrations, the incidence of hypospadias increased gradually. DEHP inhibited the key enzymes involved in steroid synthesis, resulting in decreasing testosterone synthesis. At the same time, DEHP increased reactive oxygen species (ROS) and produced inflammatory factors via NADPH oxidase-1 (NOX1) and NADPH oxidase-4 (NOX4) pathways. It also inhibited Steroid 5 α Reductase 2 (Srd5α2) and decreased dihydrotestosterone (DHT) synthesis. Additionally, DEHP inhibited the androgen receptor (AR), resulting in reduced DHT binding to the AR that ultimately retarded the development of the external reproductive system. GEN, a phytoestrogen, competes with DEHP for binding to estrogen receptor β (ERβ). This competition, along with GEN's antiestrogen and antioxidant properties, could potentially reverse impairments. The findings of this study provide valuable insights into the role of phytoestrogens in alleviating environmental estrogen-induced congenital diseases.

[Marked improvement in rheumatoid lung nodules after treatment with tocilizumab combined with glucocorticoids and leflunomide: a case report and literature review]

Rheumatoid arthritis (RA), a chronic autoimmune disorder, is characterized by erosive inflammation of bone and cartilage, leading to progressive joint destruction. Pulmonary involvement occurs in approximately 60% of RA patients, manifests most commonly as interstitial lung disease and, less commonly, as rheumatoid lung nodules. Here, we report a 50-year-old woman, non-smoker, with recurrent cough and sputum of 7 years' duration, accompanied by a chest CT showing multiple cavitary nodules in both lungs. She had been treated empirically at several medical centers and was finally diagnosed with rheumatoid lung nodules. Marked improvement in rheumatoid lung nodules was observed after treatment with tocilizumab in combination with glucocorticoids and leflunomide. The aim of this study was to improve clinicians' understanding of rheumatoid lung nodules by analyzing the clinical features, diagnosis, and treatment of this case, and reviewing the relevant medical literature.

Investigation of the ΔI=1/2 Rule and Test of CP Symmetry through the Measurement of Decay Asymmetry Parameters in Ξ^{-} Decays

Using (10087±44)×10^{6}  J/ψ events collected with the BESIII detector, numerous Ξ^{-} and Λ decay asymmetry parameters are simultaneously determined from the process J/ψ→Ξ^{-}Ξ[over ¯]^{+}→Λ(pπ^{-})π^{-}Λ[over ¯](n[over ¯]π^{0})π^{+} and its charge-conjugate channel. The precisions of α_{Λ0} for Λ→nπ^{0} and α[over ¯]_{Λ0} for Λ[over ¯]→n[over ¯]π^{0} compared to world averages are improved by factors of 4 and 1.7, respectively. The ratio of decay asymmetry parameters of Λ→nπ^{0} to that of Λ→pπ^{-}, ⟨α_{Λ0}⟩/⟨α_{Λ-}⟩, is determined to be 0.873±0.012_{-0.010}^{+0.011}, where the first and the second uncertainties are statistical and systematic, respectively. The ratio is smaller than unity more than 5σ, which signifies the existence of the ΔI=3/2 transition in Λ for the first time. Besides, we test for CP symmetry in Ξ^{-}→Λπ^{-} and in Λ→nπ^{0} with the best precision to date.

Observation of D_{s}^{+}→η^{'}μ^{+}ν_{μ}, Precision Test of Lepton Flavor Universality with D_{s}^{+}→η^{(')}l^{+}ν_{l}, and First Measurements of D_{s}^{+}→η^{(')}μ^{+}ν_{μ} Decay Dynamics

By analyzing 7.33  fb^{-1} of e^{+}e^{-} annihilation data collected at center-of-mass energies between 4.128 and 4.226 GeV with the BESIII detector, we report the observation of the semileptonic decay D_{s}^{+}→η^{'}μ^{+}ν_{μ}, with a statistical significance larger than 10σ, and the measurements of the D_{s}^{+}→ημ^{+}ν_{μ} and D_{s}^{+}→η^{'}μ^{+}ν_{μ} decay dynamics for the first time. The branching fractions of D_{s}^{+}→ημ^{+}ν_{μ} and D_{s}^{+}→η^{'}μ^{+}ν_{μ} are determined to be (2.235±0.051_{stat}±0.052_{syst})% and (0.801±0.055_{stat}±0.028_{syst})%, respectively, with precision improved by factors of 6.0 and 6.6 compared to the previous best measurements. Combined with the results for the decays D_{s}^{+}→ηe^{+}ν_{e} and D_{s}^{+}→η^{'}e^{+}ν_{e}, the ratios of the decay widths are examined both inclusively and in several ℓ^{+}ν_{ℓ} four-momentum transfer ranges. No evidence for lepton flavor universality violation is found within the current statistics. The products of the hadronic form factors f_{+,0}^{η^{(')}}(0) and the c→s Cabibbo-Kobayashi-Maskawa matrix element |V_{cs}| are determined. The results based on the two-parameter series expansion are f_{+,0}^{η}(0)|V_{cs}|=0.452±0.010_{stat}±0.007_{syst} and f_{+,0}^{η^{'}}(0)|V_{cs}|=0.504±0.037_{stat}±0.012_{syst}, which help to constrain present models on f_{+,0}^{η^{(')}}(0). The forward-backward asymmetries are determined to be ⟨A_{FB}^{η}⟩=-0.059±0.031_{stat}±0.005_{syst} and ⟨A_{FB}^{η^{'}}⟩=-0.064±0.079_{stat}±0.006_{syst} for the first time, which are consistent with the theoretical calculation.

Determination of the Σ^{+} Timelike Electromagnetic Form Factors

Based on data samples collected with the BESIII detector at the BEPCII collider, the process e^{+}e^{-}→Σ^{+}Σ[over ¯]^{-} is studied at center-of-mass energies sqrt[s]=2.3960, 2.6454, and 2.9000 GeV. Using a fully differential angular description of the final state particles, both the relative magnitude and phase information of the Σ^{+} electromagnetic form factors in the timelike region are extracted. The relative phase between the electric and magnetic form factors is determined to be sinΔΦ=-0.67±0.29(stat)±0.18(syst) at sqrt[s]=2.3960  GeV, ΔΦ=55°±19°(stat)±14°(syst) at sqrt[s]=2.6454  GeV, and 78°±22°(stat)±9°(syst) at sqrt[s]=2.9000  GeV. For the first time, the phase of the hyperon electromagnetic form factors is explored in a wide range of four-momentum transfer. The evolution of the phase along with four-momentum transfer is an important input for understanding its asymptotic behavior and the dynamics of baryons.

Utility of metagenomic Next-Generation Sequencing for simultaneously detecting pathogens and neoplasms

Objectives

Clinicians often face the challenge of differentially diagnosing febrile patients who are suspected of infectious diseases, since the clinical manifestations of infection and cancer may overlap. A single test that can detect both pathogens and tumor could provide timely and accurate diagnostic clues to aid the treatment and management of these patients.

Methods

We enrolled eight patients to evaluate the utility of metagenomic Next-Generation Sequencing for simultaneously detecting pathogens and neoplasms using body fluids and tissue samples. Patients were selected by the following criteria: 1) Tumor was not considered upon hospitalization, but mNGS testing indicated neoplasm; 2) Tumor was not excluded, but microbial infection was primarily suspected according to initial clinical assessment.

Results

We detected potential pathogens in five patients, three of whom had progressed into critical infections. Moreover, abnormal chromosomal copy numbers were identified in all patients that indicated presence of neoplasms, which were pathologically confirmed.

Conclusions

Although copy number variations do not render a definitive cancer diagnosis, it can prompt clinicians to conduct more focused diagnostic testing for cancer, potentially saving time and cost. As a result, integrating copy number analysis with pathogen detection in mNGS may help establish rapid and accurate diagnosis for febrile patients.

First Measurement of the Decay Asymmetry in the Pure W-Boson-Exchange Decay Λ_{c}^{+}→Ξ^{0}K^{+}

Based on 4.4  fb^{-1} of e^{+}e^{-} annihilation data collected at the center-of-mass energies between 4.60 and 4.70 GeV with the BESIII detector at the BEPCII collider, the pure W-boson-exchange decay Λ_{c}^{+}→Ξ^{0}K^{+} is studied with a full angular analysis. The corresponding decay asymmetry is measured for the first time to be α_{Ξ^{0}K^{+}}=0.01±0.16(stat)±0.03(syst). This result reflects the noninterference effect between the S- and P-wave amplitudes. The phase shift between S- and P-wave amplitudes has two solutions, which are δ_{p}-δ_{s}=-1.55±0.25(stat)±0.05(syst)  rad or 1.59±0.25(stat)±0.05(syst)  rad.

Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer

PURPOSE

This research designeded to: 1. Analyze the efficacy and safety of Palbociclib treatment in HR-positive and HER2-negative (HR + /HER2-) metastatic breast cancer(MBC) patients. 2. Establish and validate a nomogram model for predicting the progression-free survival (PFS) rates of 6 months, 12 months, and 18 months in HR + /HER2- MBC patients after receiving Palbociclib plus endocrine therapy (ET).

PATIENTS AND METHODS

1. This research retrospectively analyzed the efficacy and safety of Palbociclib combined with ET in 214 patients with HR + /HER2- MBC. 2. A nomogram was designed and constructed with the retrospective clinical data of 214 patients with HR + /HER2- MBC who received Palbociclib plus ET at Zhejiang Cancer Hospital in China from August 2018 to August 2022. Among these patients, 161 were randomly assigned to the training cohort, while 53 to the validation cohort. The predictive accuracy of the nomogram was assessed through the analysis the area under the receiver operating characteristic(ROC) curve, calibration curve, and decision curve analysis(DCA).

RESULTS

1. Median PFS was 7.17 months (95% CI: 7.61-10.05 months), with an objective response rate (ORR) of 2.80% and a disease control rate (DCR) of 34.58%. The most prevalent grade 3-4 adverse event was neutropenia (38.79%). 2. Multiple variable analysis of the training set revealed that age < 60 years old, PR < 20%, Ki-67 ≥ 20%, luminal B molecular subtype, primary resistance to ET, receipt of late-stage chemotherapy, and presence of liver metastasis or ≥ 2 visceral metastases were independent prognostic factors associated with poor PFS (P < 0.05). Then, the predictive model underwent development and validation utilizing the aforementioned parameters. On the one hand, the area under the ROC curve (AUC) values of the training set at 6 months, 12 months, and 18 months were 0.771, 0.783, and 0.790, respectively, indicating a strong predictive ability of the developed model. On the other hand, the AUC of the validation set at 6 months, 12 months, and 18 months were 0.720, 0.766, and 0.754, respectively, suggesting the favorable discriminatory ability of the model. The calibration curves also exhibited a good fit with the ideal curves, and the DCA demonstrated the clinical applicability of the model. The nomogram's different scores could distinguish PFS.

CONCLUSION

This retrospective study demonstrates the efficacy of Palbociclib in Chinese breast cancer patients. Moreover, the clinical parameters showed a significant association with the prognosis of HR + /HER2- MBC, and the prognostic models constructed based on these variables also displayed robust predictive power, which could offer more intuitive and convenient references for clinical doctors to formulate follow-up treatment plans.

Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial

The combination of immune-checkpoint blockade with chemotherapy for the first-line treatment of advanced triple-negative breast cancer (TNBC) has generated mixed results. TORCHLIGHT is a randomized, double-blinded phase 3 trial evaluating the efficacy and safety of first-line toripalimab and nab-paclitaxel (nab-P) (n = 353; experimental arm) versus placebo and nab-P (n = 178; control arm) for the treatment of women with metastatic or recurrent TNBC. The primary end point was progression-free survival (PFS) assessed by a blinded independent central review in the PD-L1-positive and intention-to-treat populations. The secondary end points included overall survival and safety. Overall, 200 and 100 patients, in the toripalimab and placebo arm respectively had PD-L1-positive TNBC. At the prespecified interim analysis, a statistically significant improvement in PFS assessed by a blinded independent central review was demonstrated in the experimental arm in the PD-L1-positive population (median PFS 8.4 versus 5.6 months; hazard ratio (HR) = 0.65, 95% confidence interval (CI) 0.470-0.906, P = 0.0102). The median overall survival was 32.8 versus 19.5 months (HR = 0.62, 95% CI 0.414-0.914, P = 0.0148). Similar incidences of treatment-emergent adverse events (AEs) (99.2% versus 98.9%), grade ≥3 treatment-emergent AEs (56.4% versus 54.3%) and fatal AEs (0.6% versus 3.4%) occurred in the experimental and control arms. The addition of toripalimab to nab-P provided a significant improvement in PFS for PD-L1-positive patients with metastatic or recurrent TNBC with an acceptable safety profile. ClinicalTrial.gov identifier NCT03777579 .

Expert Consensus on the Diagnosis and Treatment of NRG1/2 Gene Fusion Solid Tumors

The fusion genes NRG1 and NRG2 , members of the epidermal growth factor (EGF) receptor family, have emerged as key drivers in cancer. Upon fusion, NRG1 retains its EGF-like active domain, binds to the ERBB ligand family, and triggers intracellular signaling cascades, promoting uncontrolled cell proliferation. The incidence of NRG1 gene fusion varies across cancer types, with lung cancer being the most prevalent at 0.19 to 0.27%. CD74 and SLC3A2 are the most frequently observed fusion partners. RNA-based next-generation sequencing is the primary method for detecting NRG1 and NRG2 gene fusions, whereas pERBB3 immunohistochemistry can serve as a rapid prescreening tool for identifying NRG1 -positive patients. Currently, there are no approved targeted drugs for NRG1 and NRG2 . Common treatment approaches involve pan-ERBB inhibitors, small molecule inhibitors targeting ERBB2 or ERBB3, and monoclonal antibodies. Given the current landscape of NRG1 and NRG2 in solid tumors, a consensus among diagnostic and treatment experts is proposed, and clinical trials hold promise for benefiting more patients with NRG1 and NRG2 gene fusion solid tumors.

Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trial

The role of pyrotinib in the treatment of HER2-positive metastatic breast cancer (MBC) has been well-established. This multicenter, single-arm phase II trial (NCT03876587) aimed to assess the benefit of pyrotinib plus docetaxel as a first-line treatment for HER2-positive MBC. Women with HER2-positive MBC who had not undergone HER2 blockade or chemotherapy for metastatic disease were enrolled in the study and received daily oral pyrotinib 400 mg plus intravenous docetaxel 75 mg/m2 every 3 weeks. The primary endpoint was the objective response rate (ORR), secondary endpoints included progression-free survival (PFS), duration of response (DoR), clinical benefit rate (CBR), overall survival (OS) and safety. From June 2019 to June 2021, 79 patients were enrolled. The confirmed ORR was 79.7% (95% confidence interval [CI], 70.8-88.6), and the CBR was 87.3% (95%CI, 80.0-94.6) in the intention-to-treat population. The pre-specified primary endpoint was met. The median DoR was 15.9 months (interquartile range, 8.3-19.5); the median PFS was 16.0 months (95% CI, 11.2-20.8), and the median OS was not reached. The most common grade ≥3 treatment-related adverse events observed were leukopenia (29.1%), neutropenia (27.8%), and diarrhea (21.5%). This study demonstrates that pyrotinib plus docetaxel show an acceptable safety profile and promising antitumor activity as a first-line treatment option for patients with HER2-positive MBC.

Real-world treatment patterns and outcomes of pyrotinib-based therapy in patients with HER2-positive advanced breast cancer (PRETTY): A nationwide, prospective, observational study

Pyrotinib, an irreversible pan-ErbB inhibitor, has been approved for treating HER2-positive advanced breast cancer in China. We conducted a nationwide, prospective observational study to examine the real-world data of pyrotinib-based therapy in this population. Patients from 61 sites across China were included. Pyrotinib-based regimens were prescribed at local physician's discretion. Demographics, treatment patterns, prognosis and safety were evaluated. The primary outcome was real-world progression-free survival (rwPFS). Of 1129 patients, pyrotinib-based therapy was prescribed as first-, second- and third- or later-line treatment in 437 (38.7%), 476 (42.2%) and 216 (19.1%) patients, respectively. Median rwPFS (mrwPFS) was 14.3 (95% CI, 13.3-15.2) months in the total population, with the longest mrwPFS of 17.8 (95% CI, 15.2-24.9) months in the first-line setting, followed by 14.4 (95% CI, 12.9-15.3) months in the second-line setting. Patients with third- or later-line treatment also achieved a mrwPFS of 9.3 (95% CI, 8.4-11.8) months. Patients with trastuzumab- or trastuzumab-pertuzumab-treated disease achieved a mrwPFS of 14.3 and 13.6 months, respectively. Dual HER2 blockade with pyrotinib plus trastuzumab showed a mrwPFS of 16.2 months in the total population, with data not mature in the first-line setting. For patients with baseline brain metastases, the mrwPFS was 11.7 months. The most common adverse event was diarrhea (any grade, 73.5%; grade ≥ 3, 15.3%). In real world, pyrotinib-based therapy shows promising effectiveness in the first-, as well as second- and later-line treatment, with acceptable tolerability. Further investigations regarding front-line use or novel combinations of pyrotinib might facilitate to maximize its anti-tumor potential.

[Investigate the role of neutrophil extracellular traps in immune checkpoint inhibitor-associated myocarditis with programmed death protein-1 inhibitors involvement]

Objective: To investigate the role of neutrophil extracellular traps (NETs) in immune checkpoint inhibitor-associated myocarditis (ICIAM) with programmed death protein-1 (PD-1) inhibitors involvement, and to explore the therapeutic potential of targeting NETs in the treatment of ICIAM. Methods: Thirty 6-week-old male BALB/c mice were randomly divided into control group (n=10), myocarditis group (n=10), and treatment group (n=10). Apart from the control group, each mouse was subcutaneously injected with 100 μl of complete Freund's adjuvant containing 250 μg of mouse cardiac troponin I peptide on the 1st and 7th day. Starting on the 8th day, PD-1 inhibitor (15 μg/per mouse) was intraperitoneally injected every other day for a total of 5 times. Since 1 day before the beginning of PD-1+TnI injection, the treatment group was injected with PF-1355 (50 mg·kg-1·d-1) for 16 consecutive days. The mice's general state was observed during the whole process. Real-time fluorescence quantitative PCR (RTFQ-PCR) was carried out to evaluate the transcriptional regulation of neutrophil related chemokines, NETs, pyronecrosis related factors and proinflammatory cytokines. Immunohistochemistry, immunofluorescence and western blot were applied to determine the changes of pyrosis related molecules. Echocardiography showed the differences of main cardiac indexes while cardiac pathology compared the degree of inflammatory infiltration in 3 gruops. Results: The immunofluorescence intensity of myocardial NETs in the myocarditis group was significantly increased compared to the control group mice (2.49±0.08 and 0.99±0.26, P<0.001). The protein expression levels of pyroptosis-related NLRP3, cleaved-Caspase 1, Caspase 1, cleaved-GSDMD, GSDMD, IL-1β and IL-18 in myocardial tissue of the model group were higher than those of the control group (all P<0.05). After treatment with PF-1355, compared to the myocarditis group, the left ventricular ejection fraction (LVEF) (73.58%±5.31% and 58.12%±3.19%, P<0.001) and left ventricular fraction shortening (LVFS) (39.78%±4.31% and 33.89%±2.19%, P<0.001) increased. H-E staining showed a reduction in inflammatory infiltration area in the treatment group compared to the myocarditis group (30.12%±3.57% and 14.92%±2.46%, P<0.001). The immunofluorescence intensity of NETs decreased in the treatment group compared to the myocarditis group (2.52±0.04 and 1.03±0.05, P<0.001). The levels of NLRP3 and other pyroptosis-related molecules were downregulated in the treatment group compared to the myocarditis group (all P<0.05). Conclusions: NETs lead to myocardial cell pyroptosis by activating the NLRP3 inflammasome in PD-1 inhibitor-associated myocarditis. The specific MPO inhibitor PF-1355 shows a therapeutic potential by regulating the formation of NETs, decreasing NLRP3 level and relieving myocardial pyroptosis, thus reducing myocardial damage.

Test of CP Symmetry in Hyperon to Neutron Decays

The quantum entangled J/ψ→Σ^{+}Σ[over ¯]^{-} pairs from (1.0087±0.0044)×10^{10}  J/ψ events taken by the BESIII detector are used to study the nonleptonic two-body weak decays Σ^{+}→nπ^{+} and Σ[over ¯]^{-}→n[over ¯]π^{-}. The CP-odd weak decay parameters of the decays Σ^{+}→nπ^{+} (α_{+}) and Σ[over ¯]^{-}→n[over ¯]π^{-} (α[over ¯]_{-}) are determined to be 0.0481±0.0031_{stat}±0.0019_{syst} and -0.0565±0.0047_{stat}±0.0022_{syst}, respectively. The decay parameter α[over ¯]_{-} is measured for the first time, and the accuracy of α_{+} is improved by a factor of 4 compared to the previous results. The simultaneously determined decay parameters allow the first precision CP symmetry test for any hyperon decay with a neutron in the final state with the measurement of A_{CP}=(α_{+}+α[over ¯]_{-})/(α_{+}-α[over ¯]_{-})=-0.080±0.052_{stat}±0.028_{syst}. Assuming CP conservation, the average decay parameter is determined as ⟨α_{+}⟩=(α_{+}-α[over ¯]_{-})/2=-0.0506±0.0026_{stat}±0.0019_{syst}, while the ratios α_{+}/α_{0} and α[over ¯]_{-}/α[over ¯]_{0} are -0.0490±0.0032_{stat}±0.0021_{syst} and -0.0571±0.0053_{stat}±0.0032_{syst}, where α_{0} and α[over ¯]_{0} are the decay parameters of the decays Σ^{+}→pπ^{0} and Σ[over ¯]^{-}→p[over ¯]π^{0}, respectively.

Measurement of Energy-Dependent Pair-Production Cross Section and Electromagnetic Form Factors of a Charmed Baryon

We study the process e^{+}e^{-}→Λ_{c}^{+}Λ[over ¯]_{c}^{-} at twelve center-of-mass energies from 4.6119 to 4.9509 GeV using data samples collected by the BESIII detector at the BEPCII collider. The Born cross sections and effective form factors (|G_{eff}|) are determined with unprecedented precision after combining the single and double-tag methods based on the decay process Λ_{c}^{+}→pK^{-}π^{+}. Flat cross sections around 4.63 GeV are obtained and no indication of the resonant structure Y(4630), as reported by Belle, is found. In addition, no oscillatory behavior is discerned in the |G_{eff}| energy dependence of Λ_{c}^{+}, in contrast to what is seen for the proton and neutron cases. Analyzing the cross section together with the polar-angle distribution of the Λ_{c}^{+} baryon at each energy point, the moduli of electric and magnetic form factors (|G_{E}| and |G_{M}|) are extracted and separated. For the first time, the energy dependence of the form factor ratio |G_{E}/G_{M}| is observed, which can be well described by an oscillatory function.

Afterglow Phosphor Goes Transparent

Recently, transparent afterglow phosphors have attracted increasing interest due to the mitigated self-absorption and the ensuing improved light output, which have inspired many advanced applications, including volumetric display and three-dimensional optical encryption. To date, the most successful afterglow phosphors remain those traditional oxide, nitride, or sulfide powders which are not transparent due to a severe scattering effect. By reduction of the number of interfaces and engineering the refractive index, the scattering effect could be circumvented effectively. To this end, four material systems, including transparent afterglow single crystals, transparent phosphorescent organics, transparent afterglow glass, and luminescent nanocomposites, were reviewed in this Perspective. We started with the discussion of the nontransparency origin. Through a careful inspection of Rayleigh scattering theory, a general solution involving both refractive index and particle size was proposed to reduce the scattering effect. Many representative works on transparent afterglow phosphors were systematically reviewed, where the typical synthesis methods and the advantages and disadvantages of each system were critically presented. In the last part, bottlenecks, prospects, and future development directions based on transparent afterglow phosphors are proposed.

Early versus delayed computed tomography-guided celiac plexus neurolysis for palliative pain management in patients with advanced pancreatic cancer: a retrospective cohort study

Introduction

Abdominal and back pain is the most frequent symptom in patients with pancreatic cancer, with pain management being extremely challenging. This study aimed to evaluate pain control, opioid consumption, pain-interfered quality of life, and survival after early and delayed computed tomography (CT)-guided celiac plexus neurolysis (CPN).

Methods

A retrospective analysis of pancreatic cancer patients receiving CPN for pain (n = 56) between June 2018 and June 2021 was done. The patients were grouped as early group (n = 22) and delayed group (n = 34) on the basis of the presence of persistent refractory pain according to expert consensus on refractory cancer pain.

Results

Both groups were comparable in demographic characteristics and baseline pain conditions measured using the numeric rating scale (5.77 ± 1.23 vs. 6.27 ± 1.21; p = 0.141). The pain scores were significantly reduced in both groups; early CPN resulted in significantly lower scores from 3 to 5 months. The opioid consumption gradually decreased to a minimum at 2 weeks but increased at 1 month (35.56 ± 30.14 mg and 50.48 ± 47.90 mg, respectively); significantly larger consumption from 2 to 4 months was seen in the delayed group. The total pain interference was lower than baseline in all patients, with significant improvement after early CPN in sleep, appetite, enjoyment of life, and mood. The average survival time of the two groups was comparable.

Conclusion

Early application of CT-guided CPN for patients with advanced pancreatic cancer may help reduce pain exacerbation and opioids consumption, without influencing the survival.

Impact of air pollution changes and meteorology on asthma outpatient visits in a megacity in North China Plain

The effects of air pollution and meteorology on asthma is less studied in North China Plain. In the last decade, air quality in this region is markedly mitigated. This study compared the short-term effects of air pollutants on daily asthma outpatient visits (AOV) within different sex and age groups from 2014 to 2016 and 2017-2019 in Tianjin, with the application of distributed lag nonlinear model. Moreover, relative humidity (RH) and temperature as well as the synergistic impact with air pollutants were assessed. Air pollutants-associated risk with linear (different reference values were used) and non-linear assumptions were compared. In 2014-2016, PM10 and PM2.5 exhibited a larger impact on AOV, with the corresponding cumulative excess risks (ER) for every 10 μg/m3 increase at 1.04 % (95%CI:0.67-1.40 %, similarly hereafter) and 0.79 % (0.35-1.23 %), as well as increased to 43 % (26-63 %) and 20 % (10-31 %) at severe pollution. In 2017-2019, NO2 and MDA8 O3 exhibited a larger impact on AOV, with a cumulative ER for every 10 μg/m3 increase at 1.0 (0.63-1.4 %) and 0.36 % (0.15-0.57 %), with corresponding values of 7.9 % (4.8-11 %) and 5.6 % (2.3-9.0 %), at severe pollution. SO2 associated risk was only significant from 2014 to 2016. Cold effect, including extremely low temperature exposure and sharp temperature drop could generate a pronounced increase in AOV at 9.6 % (3.8-16 %) and 24 % (9.1-41 %), respectively. Moderate low temperature combined with air pollutants can enhance AOV during winter. Higher temperature in spring and autumn could trigger asthma by increasing pollen levels. Low RH resulted in AOV increase by 4.6 % (2.4-6.9), while higher RH generated AOV increase by 3.4 % (1.6-5.3). Females, children, and older adults tended to have a higher risk for air pollution, non-optimum temperature, and RH. As air pollution-associated risks on AOV tends to be weaker due to air quality improvement in recent years, the impact of extreme meteorological condition amidst climate change on asthma visits warrants further attention.

Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial

OBJECTIVE

To assess the efficacy and safety of pyrotinib (an irreversible pan-HER (human epidermal growth factor receptor) inhibitor), trastuzumab, and docetaxel compared with placebo, trastuzumab, and docetaxel for untreated HER2 positive metastatic breast cancer.

DESIGN

Randomised, double blind, placebo controlled, multicentre, phase 3 trial.

SETTING

40 centres in China between 6 May 2019 and 17 January 2022.

PARTICIPANTS

590 female patients (median age 52 (interquartile range 46-58) years) with untreated HER2 positive metastatic breast cancer.

INTERVENTIONS

Eligible patients were randomised 1:1 to receive either oral pyrotinib (400 mg once daily) or placebo, both combined with intravenous trastuzumab (8 mg/kg in cycle 1 and 6 mg/kg in subsequent cycles) and docetaxel (75 mg/m2) on day 1 of each 21 day cycle. Randomisation was stratified by treatment history of trastuzumab in the (neo)adjuvant setting and hormone receptor status. Patients, investigators, and the sponsor's study team were masked to treatment assignment.

MAIN OUTCOME MEASURES

The primary endpoint was progression-free survival as assessed by the investigator.

RESULTS

Of the 590 randomised patients, 297 received pyrotinib, trastuzumab, and docetaxel treatment (pyrotinib group), and 293 received placebo, trastuzumab, and docetaxel treatment (placebo group). At data cut-off on 25 May 2022, the median follow-up was 15.5 months. The median progression-free survival according to the investigator was significantly longer in the pyrotinib group than in the placebo group (24.3 (95% confidence interval 19.1 to 33.0) months versus 10.4 (9.3 to 12.3) months; hazard ratio 0.41 (95% confidence interval 0.32 to 0.53); one sided P<0.001). Treatment related adverse events of grade 3 or higher were reported in 267 (90%) of the 297 patients in the pyrotinib group and 224 (76%) of the 293 patients in the placebo group. No treatment related deaths occurred in the pyrotinib group, and one (<1%; diabetic hyperosmolar coma) treatment related death occurred in the placebo group. Survival and toxicities are still under assessment with longer follow-up.

CONCLUSIONS

Pyrotinib, trastuzumab, and docetaxel showed superiority by significantly improving progression-free survival compared with placebo, trastuzumab, and docetaxel in patients with untreated HER2 positive metastatic breast cancer. The toxicity was manageable. The findings support this dual anti-HER2 regimen as an alternative first line treatment option in this patient population.

TRIAL REGISTRATION

ClinicalTrials.gov NCT03863223.

[Investigation and analysis of clinical application of stainless steel crowns for primary molars in 2013 and 2022]

Objective: To provide references for the clinical popularization of stainless steel crowns by analyzing the clinical application and affecting factors of stainless steel crowns used in primary molars based on a questionnaire survey. Methods: Pediatric dentists from all over the country in June to December 2013 and June to December 2022 were selected to answer the survey questionnaire through the online or offline methods for analyzing the clinical application and influencing factors of stainless steel crowns used in primary molars. Results: A total of 712 and 580 questionnaires were distributed, and 608 and 512 valid questionnaires were recovered respectively in 2013 and 2022. The effective rates of the questionnaires were 85.4% and 88.3%. Among them, the usage rates of stainless steel crowns in 2013 and 2022 were 52.6% (320/608) and 78.1% (400/512) respectively, with a statistically significant difference (χ2=78.68, P<0.001). The main reasons for not selecting stainless steel crowns in 2013 were high technical sensitivity [52.8% (152/288)], followed by the impact of crown edge on gingiva [50.0% (144/288)] and poor aesthetics [27.8% (80/288)], while in 2022 were the inadequate equipage in hospitals [53.6% (60/112)] and poor aesthetics [21.4% (24/112)]. The main reasons for choosing stainless steel crowns restoration were good protection effect, less tooth fracture [78.1% (250/320) in 2013 and 82.5% (330/400) in 2022], followed by low dropout rate [62.5% (200/320) in 2013 and 68.0% (272/400) in 2022]. The proportions of stainless steel crowns restoration for primary molars after root canal therapy were 51.3% (312/608) and 76.6% (392/512) respectively with statistically significant (χ2=75.88, P<0.001). The proportions after pulp capping treatment for deep caries were 13.2% (80/608) and 53.1% (272/512) respectively, and the difference was statistically significant (χ2=206.01,P<0.001). Conclusions: During the 10 years from 2013 to 2022, the technical sensitivity of stainless steel crowns had gradually decreased, and the application in China had gradually increased. However, some hospitals have not yet equipped, which limits the application of stainless steel crowns. Therefore, training efforts should be derived to promote the clinical popularization of stainless steel crowns.

[Analysis of short-term efficacy of perioperative fecal microbiota transplantation combined with nutritional support in patients with radiation-induced enteritis complicated by intestinal obstruction]

Objective: To explore the short-term efficacy of perioperative fecal microbiota transplantation combined with nutritional support in patients with radiation-induced enteritis complicated by intestinal obstruction. Methods: The cohort of this prospective cohort study comprised 45 patients (nine men and 36 women) with radiation-induced enteritis complicated by intestinal obstruction admitted to Shanghai Tenth People's Hospital Affiliated to Tongji University from January 2022 to October 2022. The median age was 53 (42-65) years. Thirty-five of the patients had gynecological tumors and 10 colorectal malignancies. The patients were randomly allocated to a fecal microbiota transplantation group of 20 patients who underwent fecal microbiota transplantation starting 2 weeks before surgery for 6 days, in addition to receiving conventional perioperative treatment, and a conventional treatment group of 25 patients who only received nutritional support during the perioperative period. There were no significant differences in baseline characteristics (sex, age, preoperative nutritional indices, and surgical procedure) between the two groups (all P>0.05). Postoperative recovery (time to passing flatus or a bowel movement, length of stay) and complications were compared between the two groups. Postoperative complications within 30 days after surgery classified in accordance with the international Clavien-Dindo classification of surgical complications (I-V) were statistically analyzed. Improvement in gastrointestinal symptoms, namely abdominal pain, distension, diarrhea, and rectal bleeding) and gastrointestinal quality of life scores (which include 36 problems rated 0-144 points related to physical, psychological, social activities and family life; the lower the score, the more severe the symptoms) were compared between the two groups. Nutritional recovery was assessed by body mass, body mass index, total protein, albumin, prealbumin, and hemoglobin. Results: Compared with the conventional treatment group, the postoperative hospital stay was shorter in the fecal microbiota transplantation group (8.0±4.3 days vs. 11.2±5.4 days, t=2.157, P=0.037) and the time to passage of flatus or having a bowel movement was earlier (2.2±3.2 days vs. 3.9±2.3 days, t=2.072, P=0.044). There were 26 postoperative complications in the fecal microbiota transplantation group and 59 in the conventional treatment group. There were 20 and 36 Grade I to II complications and no and three Grade III to V complications in the transplantation and conventional treatment group, respectively. The overall grade of complication did not differ significantly between the two groups (P=0.544). However, the incidence of postoperative intestinal inflammatory obstruction was lower in the fecal microbiota transplantation than the conventional treatment group (10.0% [2/20] vs. 40.0% [10/25], P=0.040). One patient in the conventional treatment group died. This patient had complete intestinal obstruction complicated by severe malnutrition preoperatively, and an intestinal fistula complicated by abdominal infection postoperatively, and died despite active treatment. Nineteen and 23 patients in the transplantation and conventional treatment group, respectively, attended for follow-up 1 month after surgery; 19 and 21, respectively, attended for follow-up 3 months after surgery, and 17 and 20, respectively, attended for follow-up 6 months after surgery. There were no significant differences between the two groups in abdominal pain or rectal bleeding 1, 3, or 6 months after surgery (all P>0.05). One month after surgery, the incidence of abdominal distension and diarrhea was lower in the fecal microbiota transplantation than in the conventional treatment group (3/19 vs. 48.0% [11/23], P=0.048; 3/19 vs. 52.2% [12/23], P=0.023). However, at the 3 and 6 month follow-ups the incidence of abdominal distension and diarrhea had gradually decreased in both groups and the differences between the groups were not statistically significant (P>0.05 for all). Scores for gastrointestinal quality of life improved significantly in both treatment groups compared with preoperative values (F=71.250, P<0.001; F=79.130, P<0.001, respectively). Scores for gastrointestinal quality of life were higher in the fecal microbiota transplantation than the conventional treatment group at all follow-up time points (P<0.05). One-way ANOVA showed that body mass, body mass index, and total protein, albumin and hemoglobin concentrations improved in both groups compared with preoperative values (all P<0.05). Prealbumin concentration improved significantly in the transplantation (F=5.514, P=0.002), but not in the conventional, group (F=1.535, P=0.211). The improvements in body mass, body mass index, total protein, and albumin were better in the fecal microbiota transplantation than conventional treatment group at 3 and 6 months of follow-up (all P<0.05). Conclusion: Perioperative fecal microbiota transplantation combined with nutritional support is effective in improving early postoperative nutritional status and quality of life in patients with radiation-induced enteritis complicated by intestinal obstruction.

Response of soil extracellular enzyme activity and stoichiometry to short-term warming and phosphorus addition in desert steppe

Background

Phosphorus (P) is regarded as one of the major limiting factors in grassland ecosystems. Soil available phosphorus deficiency could affect soil extracellular enzyme activity, which is essential for microbial metabolism. Yet it is still unclear how soil available phosphorus affects soil extracellular enzyme activity and microbial nutrient limitation of desert steppe in the context of climate warming.

Methods

This study carried out a short-term open-top chambers (OTCs) experiment in a desert steppe to examine the effects of warming, P addition, and their interaction on soil properties, the activities of soil extracellular enzymes, and stoichiometries.

Results

The findings demonstrated that soil acquisition enzyme stoichiometry of C: N: P was 1.2:1:1.5 in this experiment region, which deviated from the global mean scale (1:1:1). Warming increased soil AN (ammonium nitrogen and nitrate nitrogen) contents and decreased microbial biomass carbon (MBC) and microbial biomass nitrogen (MBN). Phosphorus addition raised soil available phosphorus and microbial biomass phosphorus (MBP) contents. Soil extracellular enzyme activities and stoichiometries in desert steppe are largely impacted by soil AN, MBC: MBP, and MBN: MBP. These results revealed that the changes of soil available nutrients and stoichiometries induced by short-term warming and P addition could influence soil microbial activities and alleviate soil microbial carbon and phosphorus limitation. Our findings highlight that soil available phosphorus played a critical role in regulating soil extracellular enzyme activity and microbial nutrient limitation of desert steppe. Further research on soil microbial communities should explore the microbiological mechanisms underlying these findings.

[Expert consensus on endocrine therapy of breast cancer (2023 edition)]

Endocrine therapy is the primary systemic therapy for hormone receptor-positive breast cancer, which runs through the whole process of treatment for early and metastatic breast cancer. The development of new endocrine agents and targeted drugs such as cyclin-dependent kinases 4/6(CDK4/6)inhibitors has improved outcome of patients with hormone receptor-positive breast cancer and changed the treatment landscape. The update of clinical research data provides more treatment options, calling for treatment optimization. Experts had a deep discussion around the hot topics on endocrine therapy of breast cancer, and formulated the'Expert consensus on endocrine therapy of breast cancer (2023 edition)'.This consensus is based on research data worldwide and clinical practice experience, with the aims of standardizing clinical diagnosis and optimizing treatment in neoadjuvant, adjuvant and metastatic setting of hormone receptor-positive breast cancer.

Determination of Spin-Parity Quantum Numbers for the Narrow Structure near the pΛ[over ¯] Threshold in e^{+}e^{-}→pK^{-}Λ[over ¯]+c.c

A narrow structure in the pΛ[over ¯] system near the mass threshold, named as X(2085), is observed in the process e^{+}e^{-}→pK^{-}Λ[over ¯] with a statistical significance greater than 20σ. Its spin and parity are determined for the first time to be J^{P}=1^{+} in an amplitude analysis, with a statistical significance greater than 5σ over other quantum numbers (0^{-},1^{-} and 2^{+}). The pole positions of X(2085) are measured to be M_{pole}=(2084_{-2}^{+4}±9)  MeV and Γ_{pole}=(58_{-3}^{+4}±25)  MeV, where the first uncertainties are statistical and the second ones are systematic. The analysis is based on the study of the process e^{+}e^{-}→pK^{-}Λ[over ¯] and uses the data samples collected with the BESIII detector at the center-of-mass energies sqrt[s]=4.008, 4.178, 4.226, 4.258, 4.416, and 4.682 GeV with a total integrated luminosity of 8.35  fb^{-1}.

Precise Measurement of the e^{+}e^{-}→D_{s}^{*+}D_{s}^{*-} Cross Sections at Center-of-Mass Energies from Threshold to 4.95 GeV

The process e^{+}e^{-}→D_{s}^{*+}D_{s}^{*-} is studied with a semi-inclusive method using data samples at center-of-mass energies from threshold to 4.95 GeV collected with the BESIII detector operating at the Beijing Electron Positron Collider. The Born cross sections of the process are measured for the first time with high precision in this energy region. Two resonance structures are observed in the energy-dependent cross sections around 4.2 and 4.4 GeV. By fitting the cross sections with a coherent sum of three Breit-Wigner amplitudes and one phase-space amplitude, the two significant structures are assigned masses of (4186.8±8.7±30) and (4414.6±3.4±6.1)  MeV/c^{2}, widths of (55±15±53) and (122.5±7.5±8.1)  MeV, where the first errors are statistical and the second ones are systematic. The inclusion of a third Breit-Wigner amplitude is necessary to describe a structure around 4.79 GeV.

[Comparative study of benign and malignant parotid gland tumors by infrared thermal imaging]

Objective: To analyze the temperature difference of benign and malignant parotid gland tumors in preoperative infrared thermography (IRT), and to provide the basis for predicting tumor properties. Methods: The clinical data of 98 patients with parotid gland tumor admitted to the Department of Oral and maxillofacial Surgery of the First Affiliated Hospital of Bengbu Medical College, from May 2021 to April 2023 were retrospectively analyzed. There were 61 males and 37 females, aged (51.1±16.0) years (10-86 years). In addition to routine examination, the temperature difference between the lesion site of parotid gland and the contralateral mirror area was measured by infrared thermal imager in all patients one day before surgery. The maximum diameter (dmax) and location of the tumor (deep or superficial lobe) were recorded according to preoperative clinical examination and imaging examinations such as CT and ultrasound. The patients were divided into three groups by tumor size: dmax≤2 cm, 2 cm4 cm. The patients were also divided into different groups: deep lobe group and superficial lobe group (according to the tumor location), benign group and malignant group (according to postoperative pathological results). The relationship between temperature difference, pathology, size and location was analyzed. Results: There were 79 cases in the benign group and 19 cases in the malignant group. The temperature difference of the healthy and affected side in the malignant group [(1.73±0.21) ℃] was significantly higher than that in the benign group [(0.73±0.32) ℃] (t=16.70, P<0.001). There was no significant difference in temperature difference between the healthy and affected sides of tumors with different diameters (P>0.05). The temperature difference of healthy and affected side of tumor in superficial lobe [(0.97±0.50) ℃] was significantly higher than that in deep lobe [(0.67±0.44) ℃] (t=2.24, P=0.028). Conclusions: The difference of temperature difference between benign and malignant parotid gland tumors detected by IRT is statistically significant, which can be used to predict tumor properties, and has certain clinical application value.

First Experimental Study of the Purely Leptonic Decay D_{s}^{*+}→e^{+}ν_{e}

Using 7.33  fb^{-1} of e^{+}e^{-} collision data taken with the BESIII detector at the BEPCII collider, we report the first experimental study of the purely leptonic decay D_{s}^{*+}→e^{+}ν_{e}. Our data contain a signal of this decay with a statistical significance of 2.9σ. The branching fraction of D_{s}^{*+}→e^{+}ν_{e} is measured to be (2.1_{-0.9_{stat}}^{+1.2}±0.2_{syst})×10^{-5}, corresponding to an upper limit of 4.0×10^{-5} at the 90% confidence level. Taking the total width of the D_{s}^{*+} [(0.070±0.028)  keV] predicted with the radiative D_{s}^{*+} decay from the lattice QCD calculation as input, the decay constant of the D_{s}^{*+} is determined to be f_{D_{s}^{*+}}=(214_{-46_{stat}}^{+61}±44_{syst})  MeV, corresponding to an upper limit of 354 MeV at the 90% confidence level.

25-hydroxycholesterol: an integrator of antiviral ability and signaling

Cholesterol, as an important component in mammalian cells, is efficient for viral entry, replication, and assembly. Oxysterols especially hydroxylated cholesterols are recognized as novel regulators of the innate immune response. The antiviral ability of 25HC (25-Hydroxycholesterol) is uncovered due to its role as a metabolic product of the interferon-stimulated gene CH25H (cholesterol-25-hydroxylase). With the advancement of research, the biological functions of 25HC and its structural functions have been interpreted gradually. Furthermore, the underlying mechanisms of antiviral effect of 25HC are not only limited to interferon regulation. Taken up by the special biosynthetic ways and structure, 25HC contributes to modulate not only the cholesterol metabolism but also autophagy and inflammation by regulating signaling pathways. The outcome of modulation by 25HC seems to be largely dependent on the cell types, viruses and context of cell microenvironments. In this paper, we review the recent proceedings on the regulatory effect of 25HC on interferon-independent signaling pathways related to its antiviral capacity and its putative underlying mechanisms.

Mass spectrometry imaging and single-cell transcriptional profiling reveal the tissue-specific regulation of bioactive ingredient biosynthesis in Taxus leaves

Taxus leaves provide the raw industrial materials for taxol, a natural antineoplastic drug widely used in the treatment of various cancers. However, the precise distribution, biosynthesis, and transcriptional regulation of taxoids and other active components in Taxus leaves remain unknown. Matrix-assisted laser desorption/ionization-mass spectrometry imaging analysis was used to visualize various secondary metabolites in leaf sections of Taxus mairei, confirming the tissue-specific accumulation of different active metabolites. Single-cell sequencing was used to produce expression profiles of 8846 cells, with a median of 2352 genes per cell. Based on a series of cluster-specific markers, cells were grouped into 15 clusters, suggesting a high degree of cell heterogeneity in T. mairei leaves. Our data were used to create the first Taxus leaf metabolic single-cell atlas and to reveal spatial and temporal expression patterns of several secondary metabolic pathways. According to the cell-type annotation, most taxol biosynthesis genes are expressed mainly in leaf mesophyll cells; phenolic acid and flavonoid biosynthesis genes are highly expressed in leaf epidermal cells (including the stomatal complex and guard cells); and terpenoid and steroid biosynthesis genes are expressed specifically in leaf mesophyll cells. A number of novel and cell-specific transcription factors involved in secondary metabolite biosynthesis were identified, including MYB17, WRKY12, WRKY31, ERF13, GT_2, and bHLH46. Our research establishes the transcriptional landscape of major cell types in T. mairei leaves at a single-cell resolution and provides valuable resources for studying the basic principles of cell-type-specific regulation of secondary metabolism.

Utility of clinical metagenomics in diagnosing malignancies in a cohort of patients with Epstein-Barr virus positivity

Backgrounds

Differentiation between benign and malignant diseases in EBV-positive patients poses a significant challenge due to the lack of efficient diagnostic tools. Metagenomic Next-Generation Sequencing (mNGS) is commonly used to identify pathogens of patients with fevers of unknown-origin (FUO). Recent studies have extended the application of Next-Generation Sequencing (NGS) in identifying tumors in body fluids and cerebrospinal fluids. In light of these, we conducted this study to develop and apply metagenomic methods to validate their role in identifying EBV-associated malignant disease.

Methods

We enrolled 29 patients with positive EBV results in the cohort of FUO in the Department of Infectious Diseases of Huashan Hospital affiliated with Fudan University from 2018 to 2019. Upon enrollment, these patients were grouped for benign diseases, CAEBV, and malignant diseases according to their final diagnosis, and CNV analysis was retrospectively performed in 2022 using samples from 2018 to 2019.

Results

Among the 29 patients. 16 of them were diagnosed with benign diseases, 3 patients were diagnosed with CAEBV and 10 patients were with malignant diseases. 29 blood samples from 29 patients were tested for mNGS. Among all 10 patients with malignant diagnosis, CNV analysis suggested neoplasms in 9 patients. Of all 19 patients with benign or CAEBV diagnosis, 2 patients showed abnormal CNV results. The sensitivity and specificity of CNV analysis for the identification for tumors were 90% and 89.5%, separately.

Conclusions

The application of mNGS could assist in the identification of microbial infection and malignancies in EBV-related diseases. Our results demonstrate that CNV detection through mNGS is faster compared to conventional oncology tests. Moreover, the convenient collection of peripheral blood samples adds to the advantages of this approach.

Variability in chewing, ruminal fermentation, digestibility and bacterial communities between subacute ruminal acidosis-susceptible and acidosis-tolerant sheep

Sorting behaviour is a common phenomenon observed in ruminants when they are provided with a total mixed ration, which contributes to variations in the severity of subacute ruminal acidosis (SARA). Pelleted total mixed ration (PTMR) reduces sorting, but high-grain content increases acidosis risk. However, whether the variability in the severity of SARA exists in sheep fed the same high-grain PTMR is less understood. This study aimed to investigate SARA variability among individual sheep offered a high-grain PTMR, considering chewing activity, ruminal fermentation, bacterial communities and nutrient digestibility. Twenty ruminally cannulated male Hu sheep were individually housed in cages and fed a PTMR comprising 80% concentrate mix and 20% roughage. A 14-day adaptation period to the diet and facilities was provided before a 10-day sample collection period. Continuous monitoring of ruminal pH was conducted for 48 h, during which time chewing activity was also recorded. Ruminal fluid samples were collected for analysis of volatile fatty acid and microbial DNA extraction. Faecal samples were collected to measure nutrient digestibility. Based on their acidosis index, the sheep were classified into two groups: SARA-susceptible group (n = 6) and SARA-tolerant group (n = 6). The SARA-susceptible sheep exhibited a lower ruminal mean pH and minimum pH than the SARA-tolerant sheep (P < 0.05). Additionally, the SARA-susceptible group increased the acidosis index, duration and areas of pH below 5.8 and 5.6 compared to the SARA-tolerant group (P < 0.05). The SARA-susceptible group also exhibited a longer ruminating time than the SARA-tolerant group (P < 0.05). The SARA-susceptible group exhibited a tendency to increase the relative abundance of Firmicutes (P = 0.089), while simultaneously decreasing the copy number of Fibrobacter succinogenes in the rumen, as well as the digestibility of NDF and ADF compared to the SARA-tolerant group (P < 0.05). The acidosis index was found to be positively correlated with ruminating time (min/kg DM intake (DMI)) and total chewing time (min/kg DMI), but negatively correlated with the copy number of Fibrobacter succinogenes and Ruminococcus albus in the rumen. These findings indicate that there exists variability in the SARA severity among sheep when fed a high-grain PTMR, as evidenced by varied chewing activity, bacterial communities and nutrient digestibility. Ruminating time, total chewing time per kilogram of DMI as well as the copy number of Fibrobacter succinogenes and Ruminococcus albus in the rumen hold potential as indicators for assessing the severity of SARA.

[Anatomical classification of and laparoscopic surgery for left-sided colorectal cancer with persistent descending mesocolon]

Objective: To investigate anatomical morphology and classification of persistent descending mesocolon (PDM) in patients with left-sided colorectal cancer, as well as the safety of laparoscopic radical surgery for these patients. Methods: This is a descriptive study of case series. Relevant clinical data of 995 patients with left colon and rectal cancer who had undergone radical surgery in Fujian Medical University Union Hospital from July 2021 to September 2022 were extracted from the colorectal surgery database of our institution and retrospectively analyzed. Twenty-four (2.4%) were identified as PDM and their imaging data and intra-operative videos were reviewed. We determined the distribution and morphology of the descending colon and mesocolon, and evaluated the feasibility and complications of laparoscopic surgery. We classified PDM according to its anatomical characteristics as follows: Type 0: PDM combined with malrotation of the midgut or persistent ascending mesocolon; Type 1: unfixed mesocolon at the junction between transverse and descending colon; Type 2: PDM with descending colon shifted medially (Type 2A) or to the right side (Type 2B) of the abdominal aorta at the level of the origin of the inferior mesentery artery (IMA); and Type 3: the mesocolon of the descending-sigmoid junction unfixed and the descending colon shifted medially and caudally to the origin of IMA. Results: The diagnosis of PDM was determined based on preoperative imaging findings in 9 of the 24 patients (37.5%) with left-sided colorectal cancer, while the remaining diagnoses were made during intraoperative assessment. Among 24 patients, 22 were male and 2 were female. The mean age was (63±9) years. We classified PDM as follows: Type 0 accounted for 4.2% (1/24); Type 1 for 8.3% (2/24); Types 2A and 2B for 37.5% (9/24) and 25.0% (6/24), respectively; and Type 3 accounted for 25.0% (6/24). All patients with PDM had adhesions of the mesocolon that required adhesiolysis. Additionally, 20 (83.3%) of them had adhesions between the mesentery of the ileum and colon. Twelve patients (50.0%) required mobilization of the splenic flexure. The inferior mesenteric artery branches had a common trunk in 14 patients (58.3%). Twenty-four patients underwent D3 surgery without conversion to laparotomy; the origin of the IMA being preserved in 22 (91.7%) of them. Proximal colon ischemia occurred intraoperatively in two patients (8.3%) who had undergone high ligation at the origin of the IMA. One of these patients had a juxta-anal low rectal cancer and underwent intersphincteric abdominoperineal resection because of poor preoperative anal function. Laparoscopic subtotal colectomy was considered necessary for the other patient. The duration of surgery was (260±100) minutes and the median estimated blood loss was 50 (20-200) mL. The median number of No. 253 lymph nodes harvested was 3 (0-20), and one patient (4.2%) had No.253 nodal metastases. The median postoperative hospital stay was 8 (4-23) days, and the incidence of complications 16.7% (4/24). There were no instances of postoperative colon ischemia or necrosis observed. One patient (4.2%) with stage IIA rectal cancer developed Grade B (Clavien-Dindo III) anastomotic leak and underwent elective ileostomy. The other complications were Grade I-II. Conclusions: PDM is frequently associated with mesenteric adhesions. Our proposed classification can assist surgeons in identifying the descending colon and mesocolon during adhesion lysis in laparoscopic surgery. It is crucial to protect the colorectal blood supply at the resection margin to minimize the need for unplanned extended colectomy, the Hartmann procedure, or permanent stomas.

The RNA-binding protein LRPPRC promotes resistance to CDK4/6 inhibition in lung cancer

Kinase inhibitors against Cyclin Dependent Kinase 4 and 6 (CDK4/6i) are promising cancer therapeutic drugs. However, their effects are limited by primary or acquired resistance in virtually all tumor types. Here, we demonstrate that Leucine Rich Pentatricopeptide Repeat Containing (LRPPRC) controls CDK4/6i response in lung cancer by forming a feedback loop with CDK6. LRPPRC binds to CDK6-mRNA, increasing the stability and expression of CDK6. CDK6 and its downstream E2F Transcription Factor 1 (E2F1), bind to the LRPPRC promoter and elevate LRPPRC transcription. The activation of the LRPPRC-CDK6 loop facilitates cell cycle G1/S transition, oxidative phosphorylation, and cancer stem cell generation. Gossypol acetate (GAA), a gynecological medicine that has been repurposed as a degrader of LRPPRC, enhances the CDK4/6i sensitivity in vitro and in vivo. Our study reveals a mechanism responsible for CDK4/6i resistance and provides an enlightening approach to investigating the combinations of CDK4/6 and LRPPRC inhibitors in cancer therapy.

[Primary adrenal NK/T cell lymphoma: a clinicopathologic analysis of six cases]

Objective: To investigate the clinicopathologic features of primary adrenal NK/T cell lymphoma (PANKL). Methods: Six cases of PANKL were collected at Henan Provincial People's Hospital from January 2000 to December 2021. The clinicopathologic features including morphology, immunophenotype, treatment and prognosis were retrospectively analyzed, and relevant literature was reviewed. Results: There were two males and four females. The median age was 63 years (ranged from 57 to 68 years). The tumors involved bilateral adrenal glands in 4 cases and unilateral adrenal gland in 2 cases. The main clinical symptom was low back pain without obvious cause. Serum lactate dehydrogenase (LDH) is elevated in five cases. The imaging feature was rapidly enlarging mass initially confined to unilateral/bilateral adrenal glands. Morphologically, the lymphoid cells were mainly medium-sized with a diffuse growth pattern. Coagulative necrosis and nuclear fragmentation were common. Angioinvasion was seen. Immunophenotypically, the neoplastic cells were positive for CD3, CD56 and TIA-1 while CD5 was negative in 5 cases. All cases were positive for EBER by in situ hybridization with more than 80% proliferative activity by Ki-67. Four cases received chemotherapy, one case underwent surgery, and one case underwent surgery with chemotherapy. Follow-up was done in 5 cases; one case was lost to follow-up. Three patients died with a median survival of 11.6 months (3-42 months). Conclusions: PANKL is rare with highly aggressive clinical presentation and poor prognosis. Accurate diagnosis entails correlation of histomorphology, immunohistochemistry, EBER in situ hybridization and clinical history.

Preclinical and clinical activity of DZD1516, a full blood-brain barrier-penetrant, highly selective HER2 inhibitor

BACKGROUND

Patients with HER2-positive metastatic breast cancer (MBC) are at high risk of developing central nervous system (CNS) metastases. A potent and selective HER2 inhibitor with good blood-brain barrier (BBB) penetration is highly desirable.

METHODS

The design and structure-activity relationship of DZD1516 was described. The potency and selectivity of DZD1516 were determined by enzymatic and cellular assays. The antitumor activity of DZD1516 monotherapy or in combination with HER2 antibody-drug conjugate was assessed in CNS and subcutaneous xenograft mouse models. A phase 1 first-in-human study evaluated the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DZD1516 in patients with HER2+ MBC who relapsed from standard of care.

RESULTS

DZD1516 showed good selectivity against HER2 over wild-type EGFR in vitro and potent antitumor activity in vivo. Twenty-three patients were enrolled and received DZD1516 monotherapy treatment across six dose levels (25-300 mg, twice daily). Dose-limiting toxicities were reported at 300 mg, and thus 250 mg was defined as the maximum tolerated dose. The most common adverse events included headache, vomiting, and hemoglobin decreased. No diarrhea or skin rash was observed at ≤ 250 mg. The mean Kp,uu,CSF was 2.1 for DZD1516 and 0.76 for its active metabolite DZ2678. With median seven lines of prior systemic therapy, the best antitumor efficacy in intracranial, extracranial and overall lesions was stable disease.

CONCLUSIONS

DZD1516 provides positive proof of concept for an optimal HER2 inhibitor with high BBB penetration and HER2 selectivity. Further clinical evaluation of DZD1516 is warranted, with the RP2D being 250 mg BID.

CLINICALTRIALS

gov identifier NCT04509596. Registered on August 12, 2020; Chinadrugtrial: CTR20202424 Registered on December 18, 2020.

[Anatomical and histological investigation of the area anterior to the anorectum passing through the levator hiatus]

Objective: To document the anatomical structure of the area anterior to the anorectum passing through the levator hiatus between the levator ani slings bilaterally. Methods: Three male hemipelvises were examined at the Laboratory of Clinical Applied Anatomy, Fujian Medical University. (1) The anatomical assessment was performed in three ways; namely, by abdominal followed by perineal dissection, by examining serial cross-sections, and by examining median sagittal sections. (2) The series was stained with hematoxylin and eosin to enable identification of nerves, vessels, and smooth and striated muscles. Results: (1) It was found that the rectourethralis muscle is closest to the deep transverse perineal muscle where the longitudinal muscle of the rectum extends into the posteroinferior area of the membranous urethra. The communicating branches of the neurovascular bundle (NVB) were identified at the posterior edge of the rectourethralis muscle on both sides. The rectum was found to be fixed to the membranous urethra through the rectourethral muscle, contributing to the anorectal angle of the anterior rectal wall. (2) Serial cross-sections from the anal to the oral side were examined. At the level of the external anal sphincter, the longitudinal muscle of the rectum was found to extend caudally and divide into two muscle bundles on the oral side of the external anal sphincter. One of these muscle bundles angled dorsally and caudally, forming the conjoined longitudinal muscle, which was found to insert into the intersphincteric space (between the internal and external anal sphincters). The other muscle bundle angled ventrally and caudally, filling the gap between the external anal sphincter and the bulbocavernosus muscle, forming the perineal body. At the level of the superficial transverse perineal muscle, this small muscle bundle headed laterally and intertwined with the longitudinal muscle in the region of the perineal body. At the level of the rectourethralis and deep transverse perineal muscle, the external urethral sphincter was found to occupy an almost completely circular space along the membranous part of the urethra. The dorsal part of the external urethral sphincter was found to be thin at the point of attachment of the rectourethralis muscle, the ventral part of the longitudinal muscle of the rectum. We identified a venous plexus from the NVB located close to the oral and ventral side of the deep transverse perineal muscle. Many vascular branches from the NVB were found to be penetrating the longitudinal muscle and the ventral part of rectourethralis muscle at the level of the apex of the prostate. The rectourethral muscle was wrapped ventrally around the membranous urethra and apex of the prostate. The boundary between the longitudinal muscle and prostate gradually became more distinct, being located at the anterior end of the transabdominal dissection plane. (3) Histological examination showed that the dorsal part of the external urethral sphincter (striated muscle) is thin adjacent to the striated muscle fibers from the deep transverse perineal muscle and the NVB dorsally and close by. The rectourethral muscle was found to fill the space created by the internal anal sphincter, deep transverse perineal muscle, and both levator ani muscles. Many tortuous vessels and tiny nerve fibers from the NVB were identified penetrating the muscle fibers of the deep transverse perineal and rectourethral muscles. The structure of the superficial transverse perineal muscle was typical of striated muscle. These findings were reconstructed three-dimensionally. Conclusions: In intersphincteric resection or abdominoperineal resection for very low rectal cancer, the anterior dissection plane behind Denonvilliers' fascia disappears at the level of the apex of the prostate. The prostate and both NVBs should be used as landmarks during transanal dissection of the non-surgical plane. The rectourethralis muscle should be divided near the rectum side unless tumor involvement is suspected. The superficial and deep transverse perineal muscles, as well as their supplied vessels and nerve fibers from the NVB. In addition, the cutting direction should be adjusted according to the anorectal angle to minimize urethral injury.

[Clinical application and standardized implementation of intersphincteric resection]

Intersphincteric resection (ISR) is the ultimate sphincter-preserving surgical technique for low rectal cancer. To promote the standardized implementation of ISR, this review discusses the important issues regarding the clinical application of ISR with reference to the latest Chinese expert consensus on ISR. In terms of ISR-related pelvic anatomy of the rectum/anal canal, hiatal ligament is not identical with the anococcygeal ligament. At the level where the rectourethralis muscle continuously extends to the posteroinferior area of the membranous urethra from the rectum, the neurovascular bundle is identified between the posterior edge of rectourethralis muscle and the anterior edge of the longitudinal muscle of the rectum. This knowledge is crucial to detect the anterior dissection plane during ISR at the levator hiatus level. The indication criteria for ISR included: (1) stage I early low rectal cancer; (2) stage II-III low rectal cancer undergoing neoadjuvant treatment, and supra-anal tumors and juxta-anal tumors of stage ycT3NxM0, or intra-anal tumors of stage ycT2NxM0. However, signet ring cell carcinoma, mucinous adenocarcinoma and undifferentiated carcinoma should be contraindicated to ISR. For locally advanced low rectal cancer (especially anteriorly located tumor), neoadjuvant treatment should be carried out in a standardized manner. However, it should be recognized that neoadjuvant chemoradiotherapy was a risk factor for poor anal function after ISR. For surgical approaches for ISR, including transanal, transabdominal, and transanal transabdominal approaches, the choice should be based on oncological safety and functional consequences. While ensuring the negative margin, maximal preservation of rectal walls and anal canal contributs to better postoperative anorectal function. Careful attention must be paid to complications regarding ISR, with special focus on the anastomotic complications. The incidence of low anterior resection syndrome (LARS) was higher than 40%. However, this issue is often neglected by clinicians. Thus, management and rehabilitation strategies for LARS with longer follow-ups were required.